



THE HONG KONG 香港醫訊  
*MEDICAL DIARY*

[www.fmshk.org](http://www.fmshk.org)

VOL.18 NO.8 AUGUST 2013

*Minimal Invasive Surgery &  
Endoscopic Surgery*

# THUNDERBEAT & SONICBEAT REVOLUTIONARY TECHNOLOGY

## FULLY-INTEGRATED BIPOLAR AND ULTRASONIC TECHNOLOGY



Rapid dissection and reliable  
7mm vessel sealing  
in a single instrument

**BIPOLAR + ULTRASONIC  
SURGICAL TISSUE  
MANAGEMENT SYSTEM**

For more information, please contact **Olympus HK and China Limited**  
L43, Office Tower, Langham Place, 8 Argyle Street, Mongkok, Kowloon, Hong Kong  
Tel : 2170 5678 Fax : 2170 5679 [www.olympus.com.hk](http://www.olympus.com.hk)

**OLYMPUS**<sup>®</sup>

Your Vision, Our Future



## Contents

### Editorial

- **Editorial** 2  
*Prof. Michael KW LI, BBS*

### Medical Bulletin

- **The Current Status of Minimally Invasive Liver Surgery** 4  
*Dr. Eric CH LAI*  
*Prof. Michael KW LI, BBS* CME  
*Dr. Chung-ngai TANG*
- **MCHK CME Programme Self-assessment Questions** 6
- **Video-assisted Thoracoscopic Surgery Today** 8  
*Dr. Yuk-ping TAI*
- **MIS Upper GI** 10  
*Dr. Frances CHEUNG*
- **MIS - Future is Here** 14  
*Dr. Hester YS CHEUNG*
- **MIS Applications in Endocrine Pathology** 18  
*Dr. David KK TSUI*

### Press Release 23

### Federation News 24

### Society News 28

### Radiology Quiz

- **Radiology Quiz** 20  
*Dr. KS TAI*

### Medical Diary of August 29

### Calendar of Events 30

## FOR LEASE

### GOLDEN OPPORTUNITY AT SOGO

Premier Medical Office available for Lease  
at prestigious EAST POINT CENTRE  
in CAUSEWAY BAY

Starting OCTOBER.

Little to spend on renovation.

Reasonable rental with excellent  
management services.

Approximately 1,000 square feet.

Suitable for ALL MEDICAL  
and DENTAL SPECIALTIES.

Present Rental: HK\$41,000 / month all exclusive  
Government Rates: HK\$5,500 / quarter  
Management Fee: HK\$2,240 / month

Interested parties to contact Dr David Woo.  
Email: davidwoo@hotmail.com.hk  
Mob: 9100 1853

## Disclaimer

All materials published in the Hong Kong Medical Diary represent the opinions of the authors responsible for the articles and do not reflect the official views or policy of the Federation of Medical Societies of Hong Kong, member societies or the publisher.

Publication of an advertisement in the Hong Kong Medical Diary does not constitute endorsement or approval of the product or service promoted or of any claims made by the advertisers with respect to such products or services.

The Federation of Medical Societies of Hong Kong and the Hong Kong Medical Diary assume no responsibility for any injury and/or damage to persons or property arising from any use of execution of any methods, treatments, therapy, operations, instructions, ideas contained in the printed articles. Because of rapid advances in medicine, independent verification of diagnoses, treatment method and drug dosage should be made.

## The Cover Shot



### The Waterfall

This photo of the Jiuzhaigou waterfall was taken in October 2012. When I arrived at the scene, it was already evening. The last ray was shining in the last bit of the waterfall. I deliberately chose a position to shoot with the backlight on the fall against a dark background. The lighting led the water to sparkle. A diagonal composition was taken.

The leaves in the lower part of the picture acted as the foreground and were highlighted. This together with the slender tree in the right lower corner helped to stabilise the image. The grass in the upper left corner at the top of the fall echoed with the tree at the bottom that served to complete the composition. To avoid water spraying onto the camera lens and flaring artifacts from the direct light, the photo had to be taken at a distance using a telephoto lens. This also avoided the crowds.



**Dr. Amy LM PANG**  
MBBS(HK),FRCR,  
FHKCR,FHKAM(Radiology)  
Specialist in Radiology



**Published by**  
The Federation of Medical Societies of Hong Kong

**EDITOR-IN-CHIEF**

Dr. MOK Chun-on  
莫鎮安醫生

**EDITORS**

Prof. CHAN Chi-fung, Godfrey  
陳志峰教授 (Paediatrics)  
Dr. CHAN Chi-kuen  
陳志權醫生 (Gastroenterology & Hepatology)  
Dr. CHAN Sai-kiwing  
陳世烟醫生 (Dentistry)  
Dr. KING Wing-keung, Walter  
金永強醫生 (Plastic Surgery)  
Dr. LO See-kit, Raymond  
勞思傑醫生 (Geriatric Medicine)

**EDITORIAL BOARD**

Dr. AU Wing-yan, Thomas  
區永仁醫生 (Haematology and Haematological Oncology)  
Dr. CHAK Wai-kiwing  
翟偉光醫生 (Paediatrics)  
Dr. CHAN Chun-kwong, Jane  
陳真光醫生 (Respiratory Medicine)  
Dr. CHAN Hau-ngai, Kingsley  
陳厚毅醫生 (Dermatology & Venereology)  
Dr. CHAN, Norman  
陳諾醫生 (Diabetes, Endocrinology & Metabolism)  
Dr. CHEUNG Fuk-chi, Eric  
張復熾醫生 (Psychiatry)  
Dr. CHIANG Chung-seung  
蔣忠想醫生 (Cardiology)  
Prof. CHIM Chor-sang, James  
詹楚生教授 (Haematology and Haematological Oncology)  
Dr. CHONG Lai-yin  
莊禮賢醫生 (Dermatology & Venereology)  
Dr. CHUNG Chi-chiu, Cliff  
鍾志超醫生 (General Surgery)  
Dr. FONG To-sang, Dawson  
方道生醫生 (Neurosurgery)  
Dr. HSUE Chan-chee, Victor  
徐成之醫生 (Clinical Oncology)  
Dr. KWOK Po-yin, Samuel  
郭寶賢醫生 (General Surgery)  
Dr. LAM Siu-keung  
林兆強醫生 (Obstetrics & Gynaecology)  
Dr. LAM Wai-man, Wendy  
林慧文醫生 (Radiology)  
Dr. LEE Kin-man, Philip  
李健民醫生 (Oral & Maxillofacial Surgery)  
Dr. LEE Man-pui, Albert  
李文彪醫生 (Dentistry)  
Dr. LI Fuk-him, Dominic  
李福謙醫生 (Obstetrics & Gynaecology)  
Prof. LI Ka-wah, Michael, BBS  
李家驊醫生 (General Surgery)  
Dr. LO Chor Man  
盧礎文醫生 (Emergency Medicine)  
Dr. LO Kwok-wing, Patrick  
盧國榮醫生 (Diabetes, Endocrinology & Metabolism)  
Dr. MA Hon-ming, Ernest  
馬漢明醫生 (Rehabilitation)  
Dr. MAN Chi-wai  
文志衛醫生 (Urology)  
Dr. NG Wah Shan  
伍華山醫生 (Emergency Medicine)  
Dr. PANG Chi-wang, Peter  
彭志宏醫生 (Plastic Surgery)  
Dr. TSANG Kin-lun  
曾建倫醫生 (Neurology)  
Dr. TSANG Wai-kay  
曾偉基醫生 (Nephrology)  
Dr. WONG Bun-lap, Bernard  
黃品立醫生 (Cardiology)  
Dr. YAU Tsz-kok  
游子覺醫生 (Clinical Oncology)  
Prof. YU Chun-ho, Simon  
余俊豪教授 (Radiology)  
Dr. YUEN Shi-yin, Nancy  
袁淑賢醫生 (Ophthalmology)

**Design and Production**

A-PRO MULTIMEDIA LTD www.apro.com.hk

Editorial

Prof. Michael KW LI, BBS

MBBS(Lond), MRCS(Eng), LRCP(Lond), FRCS(Eng),  
FRCS(Edin), FCSHK, FHKAM(Surgery)

Professor of Surgery, University College London, United Kingdom  
Honorary Consultant in General Surgery,  
Director of Minimally Invasive & Robotic Surgery Development,  
Hong Kong Sanatorium & Hospital  
Consultant Surgeon in Department of Surgery,  
Advisor of Minimal Access Surgery Training Centre,  
Pamela Youde Nettersole Eastern Hospital,  
Hong Kong

Editor



Prof. Michael KW LI, BBS

The first laparoscopic cholecystectomy was performed in 1990 in Hong Kong at PWH. Thereafter, minimally invasive surgery (MIS) has developed a significant impact on current surgical management.

Currently, the laparoscopic approach is considered to be the standard approach for cholecystectomy and patch repair of perforated peptic ulcers. Laparoscopic appendicectomy, laparoscopic hernioplasty and laparoscopic colectomy are also widely practised in different surgery centres in Hong Kong. Patients are now benefited from better postoperative outcome and faster recovery.

With the use of the da Vinci robotic system, surgery in a confined space (e.g. in the pelvis) or those procedures with great demands on suturing (e.g. anastomosis of the GI tract) can be performed better by means of robotic techniques.

In the current issue, we share MIS applications in various surgical subspecialties. Dr. Eric LAI shares with us the current status of minimally invasive liver surgery. Dr. YP TAI illustrates the current indications for video-assisted thoracoscopic surgery. Dr. Hester CHEUNG will discuss the usage of MIS in rectal cancer and obstructing colorectal cancer. Further highlights on natural orifice transluminal endoscopic surgery (NOTES), single-port device and robotic surgery for colorectal surgery are given as well. Dr. Frances CHEUNG describes the MIS and robotic surgery for benign and neoplastic conditions in the upper gastrointestinal tract. Dr. David TSUI gives highlights on the application of MIS in various endocrine conditions including adrenal, parathyroid and thyroid pathology.

I hope our readers will enjoy reading this issue and be brought up to date with current practice of MIS.



# 日日鈣思寶™

## 膽固醇 遠離我

全靠植物固醇 為身體打好底 鈣思寶推出全新降膽固醇配方，特別加入植物固醇，組成腸道防衛線，阻隔膽固醇吸收。日日飲，日日踢走膽固醇！

Vitasoy is proud to present you the **1st** clinically proven<sup>1</sup> cholesterol-lowering beverage in Hong Kong!!!

**CALCIPLUS PLANT STEROL – The new solution for your clients with hypercholesterolemia**

#### What is plant sterol?

Plant sterols are a group of plant-derived sterols that are structurally similar and functionally analogous to cholesterol and are naturally occurring in plant foods such as soybean, nuts, seeds, legumes and cereals, but only in small amounts<sup>1</sup>. Available studies suggested the intake of plant sterol is around 150-400mg/d in a typical western diet<sup>2</sup>.

#### What does plant sterol do and how does it work?

The presence of plant sterols in the intestine interferes with the absorption of cholesterol via competitive displacement of cholesterol in micellar solubilisation and lowers cholesterol levels<sup>1</sup>. More cholesterol is removed from the body as a result.

#### What is the efficacy of plant sterol?

The intake of 2g/d of plant sterols reduces low-density lipoprotein by 10%<sup>2</sup>.

#### Who is plant sterols suitable for?

Plant sterols have been evaluated in adults with normal or high cholesterol levels, in children and in patients with type 2 diabetes to effectively lower LDL cholesterol<sup>3</sup>.

**Each pack of Calciplus Plant Sterol™ is fortified with 1g of plant sterol to provide 50% of therapeutic dose.**

#### References

- 1 Ostlund RE. Phytosterols in Human Nutrition. Ann Rev Nutr 2002;22:533-49.
- 2 Katan MB, Grundy SM, Jones P et al. Efficacy and Safety of Plant Stanols and Sterols in the Management of Blood Cholesterol Levels. Mayo Clin Proc 2003;78:965-978.
- 3 Jones PJH and AbuMweis SS. Phytosterols as Functional Food Ingredients: Linkages to Cardiovascular Disease and Cancer. Curr Opin in Clin Nutr Met Care 2009;12:147-51.

# The Current Status of Minimally Invasive Liver Surgery

**Dr. Eric CH LAI**

MBChB(CUHK), MRCS(Edin), FRACS, FCSHK, FHKAM(Surg)  
 Consultant, Department of Surgery, Pamela Youde Nethersole Eastern Hospital

**Prof. Michael KW LI, BBS**

MBBS(Lond), MRCS(Eng), LRCP(Lond), FRCS(Eng), FRCS(Edin), FCSHK, FHKAM(Surgery)  
 Professor of Surgery, University College London, United Kingdom  
 Honorary Consultant in General Surgery, Director of Minimally Invasive & Robotic Surgery Development,  
 Hong Kong Sanatorium & Hospital, Hong Kong  
 Consultant Surgeon in Department of Surgery, Advisor of Minimal Access Surgery Training Centre, Pamela  
 Youde Nethersole Eastern Hospital, Hong Kong

**Dr. Chung-ngai TANG**

MBBS(HK), FRCS(Edin), FCSHK, FHKAM(Surgery)  
 Consultant & Chief of Service, Department of Surgery, Pamela Youde Nethersole Eastern Hospital



Dr. Eric CH LAI

Prof. Michael KW LI, BBS

Dr. Chung-ngai TANG

*This article has been selected by the Editorial Board of the Hong Kong Medical Diary for participants in the CME programme of the Medical Council of Hong Kong (MCHK) to complete the following self-assessment questions in order to be awarded 1 CME credit under the programme upon returning the completed answer sheet to the Federation Secretariat on or before 30 August 2013.*

## Introduction

The introduction of minimally invasive surgery (MIS) has revolutionised surgical practice in the past two decades. MIS has been shown to be safe and effective for surgical management of several gastrointestinal conditions. MIS benefits patients in terms of aesthetics and early recovery, and medical institutions in terms of the low cost associated with a short hospital stay. Traditionally, liver surgery is considered as one of the most complex surgeries among the abdominal procedures. These advanced MIS require liver surgeons to have experienced laparoscopic skills. Therefore, its MIS development is also lagging behind other gastrointestinal organs' MIS development. In the last decade, surgeon skill, technological advances, and patient awareness have contributed to a marked growth in the field of MIS in liver surgery worldwide. Since the first laparoscopic liver resection was reported in 1992, there has been an exponential increase in the number of reported laparoscopic liver resections, and the interest in robot-assisted laparoscopic liver resections is rising also recently.<sup>1</sup> This article aims at introducing the current status of MIS in liver surgery.

## Conventional Laparoscopic Approach

The drives of development of laparoscopic liver resection are the potential MIS benefits to the patients. (Table 1) Various techniques and instruments have been developed to make this become feasible in the last 2 decades. Laparoscopic liver resection can either be total laparoscopic, hand-assisted approach or a laparoscopic-assisted open "hybrid" approach, where the operation is started laparoscopically to mobilise the liver and dissection, followed by a small laparotomy wound for completion of the parenchymal transection. Techniques of hand-assisted laparoscopy or hybrid approach has been attempted to bridge the gap between open and conventional total laparoscopic approach. Obviously, total laparoscopic procedure is superior to hand-assisted approach and hybrid approach in terms of wound pain, and cosmetic outcome.

In order to standardise and summarise the current position on laparoscopic liver surgery, an international consensus conference was convened to evaluate the status of laparoscopic liver surgery in Louisville, Kentucky, in November 2008, incorporating the opinions of the

world's experts in laparoscopic and open liver surgery.<sup>2</sup> The organising committee selected 45 recognised experts from around the world with the most extensive published experience in both laparoscopic and open liver surgery. They concluded that laparoscopic liver surgery is a safe and effective approach to the management of surgical liver disease in the hands of trained surgeons with experience in hepatobiliary and laparoscopic surgery. The best indications for laparoscopic liver resection are in patients with solitary lesions, 5 cm or less, located in peripheral liver segments (segments 2–6). The laparoscopic approach to left lateral sectionectomy should be considered as a standard practice. Although most types of liver resections can be performed laparoscopically, including major liver resections, these should be reserved to experienced surgeons already skilled at more complex laparoscopic resections. Up till the year 2009, almost 3000 laparoscopic liver resections have been reported.<sup>3</sup> Fifty percent were performed for malignant pathologies. Conversion to open laparotomy and to hand-assisted approach happened in 4.1% and 0.7% of cases, respectively. The overall mortality rate was 0.3%, and the morbidity rate was 10.5%, with 0% intra-operative mortality reported.

**Table 1: Potential advantages of minimally invasive liver surgery**

<b>Operative</b>	<ul style="list-style-type: none"> <li>• Improved visualisation</li> <li>• Visual magnification</li> <li>• Reduced blood loss</li> <li>• Decreased collateral venous drainage, especially in patients with liver cirrhosis/portal hypertension</li> <li>• Less adhesion formation</li> </ul>
<b>Post-operative recovery</b>	<ul style="list-style-type: none"> <li>• Improved perioperative pulmonary recovery</li> <li>• Fewer wound infection</li> <li>• Reduced perioperative immune suppression</li> <li>• Shorter postoperative recovery time</li> <li>• Better cosmesis</li> </ul>

Multiple series have been published on laparoscopic liver resections; however, no prospective, randomised controlled trials have been established to compare laparoscopic with open liver resections. Large cohort series, nonrandomised comparative studies, meta-analyses, and reviews have thus far attested to the feasibility and safety of laparoscopic liver resections for benign and malignant pathologies.<sup>4-10</sup> Over the past decade, this MIS approach has been used increasingly to manage various liver pathologies, showing that this technique in liver surgery, despite the technical challenges, reduces operative blood loss and results in less postoperative analgesic drugs consumption, and shorter hospital stay, with the morbidity, mortality,



oncologic clearance and survival rate similar to that of open surgery. Although these advantages may be partially explained by a strict patient selection, and surgeries performed by highly experienced laparoscopic surgeons, the place of laparoscopy in liver surgery is increasing indeed.


The majority of reported laparoscopic liver resections are non-anatomic resections or segmentectomies. Recently, some encouraging data about laparoscopic major liver resections come from large published series, but its reproducibility and routine feasibility of this technique remain questionable.<sup>11</sup> Laparoscopic major liver resection is still limited to a few expert centres, and only a small percentage of patients are considered by the majority of authors to be suitable for the laparoscopic approach.

## Robotic Approach

The recent introduction of robotic surgery has revolutionised the practice of MIS. The recently developed surgical robotic systems can overcome many of the limitations and drawbacks of conventional laparoscopic approach. Well-known advantages of the robotic surgery have allowed precise operating techniques in a variety of surgical procedures. (Table 2) These special features of precision, steadiness, and dexterity allow the surgeons to perform delicate porta hepatitis dissection, hepato-caval dissection and biliary-enteric anastomosis.<sup>12,13</sup> This may fasten and broaden the scope of MIS development of liver surgery. Hence, the technique can be used for a multitude of conditions including liver surgery that involve biliary reconstruction, liver resection for tumour in difficult positions, and major liver resection. (Figure 1 & 2)

**Table 2. Advantages and disadvantages of robotic surgery**

Advantages	
	<ul style="list-style-type: none"> <li>• 3-dimensional magnified view</li> <li>• Seven degrees of freedom with improved dexterity</li> <li>• Elimination of fulcrum effect</li> <li>• Elimination of physiologic tremors</li> <li>• Ability to scale motions</li> <li>• Facilitate anastomoses</li> <li>• Ergonomic position</li> <li>• Tele-surgery transmission</li> </ul>
Disadvantages	
	<ul style="list-style-type: none"> <li>• Complete absence of tactile feedback</li> <li>• Expensive</li> <li>• High start-up costs</li> <li>• Require extra staff to operate</li> <li>• New technology, with unproven benefit</li> </ul>



The indications and surgical principle for robotic liver resection are similar to those for conventional laparoscopic liver resection as long as patient safety and oncologic results are not compromised. Robotic approach of liver resection emphasises teamwork between two experienced laparoscopic and liver surgeons. The robotic surgeon occupies the console and the bedside surgeon sits at the side of the patient to maintain the tissue counter traction, exchange instruments, pass needles, and

manage the suction-irrigator, clip applicators, and various surgical energy devices as needed. Some people criticised the longer operating time of robotic surgery. From our experiences, it will be gradually improved after passing the learning curve. Between May 2009 to April 2013, 115 patients underwent robotic liver resections in our hepatobiliary surgical unit of Pamela Youde Nethersole Eastern Hospital. 28.2% of resections were major hepatectomies. The mean operating time, blood loss, morbidity rate, mortality rate were 213.5 minutes, 266.7 ml, 12.2% and 0%, respectively. The open conversion and hand port conversion rate was 0.9 and 1.7%, respectively. The mean hospital stay was 6 days. Although little data regarding robotic approach of liver resection have been reported in the literature, it appears to be similar to conventional laparoscopic liver resections in terms of operative time, blood loss, morbidity, mortality rate and hospital stay.<sup>14-16</sup> The other usual criticism is its costs. The costs of robotic approach of liver resection are more expensive than conventional laparoscopic liver resection due to the high costs of start-up, maintenance, and need for dedicated instruments of robotic surgery. This is a great hurdle for the development of robotic surgery for liver pathologies. To reduce its costs, it may be useful to establish high-volume centres, create specialised robotic surgery units, train dedicated theatre staff, reduce the number of disposable instruments per operation, reduce setup time, and shorten the learning curve with the help of expert surgeons at the beginning of the training period. When addressing cost savings of robotic surgery, it is also necessary to increase multidisciplinary use and overall annual use. In addition, robotic liver resection may become more popular if future designed robotic surgical systems can be developed that are smaller, less expensive, integration of haptic feedback and incorporate various hepatic parenchymal transection tools.

## Conclusion

MIS in liver surgery is entering a new era in the surgical management of liver diseases. Laparoscopic liver surgery offers the benefits of MIS, such as better cosmesis, less blood loss, reduced duration of hospitalisation, and less postoperative pain in selected patients. The technique has been shown to be as safe and feasible in experienced hands. Although little data regarding robotic liver surgery have been reported, it appears to be similar to conventional laparoscopic approach in terms of short term outcomes. MIS in liver surgery should be initiated only in centres in which the combined expertise in laparoscopic and hepatic surgery exists.

## References

1. Gagner M, Rheault M, Dubuc J. Laparoscopic partial hepatectomy for liver tumor. *Surg Endosc* 1992;6:99.
2. Buell JF, Cherqui D, Geller DA, et al; World Consensus Conference on Laparoscopic Surgery. The international position on laparoscopic liver surgery: The Louisville Statement, 2008. *Ann Surg*. 2009;250:825-30.
3. Nguyen KT, Gamblin TC, Geller DA. World review of laparoscopic liver resection-2,804 patients. *Ann Surg*. 2009;250:831-41.
4. Tang CN, Tsui KK, Ha JP, Yang GP, Li MK. A single-centre experience of 40 laparoscopic liver resections. *Hong Kong Med J*. 2006;12:419-25.
5. Lee KF, Cheung YS, Chong CN, Tsang YY, Ng WW, Ling E, Wong J, Lai PB. Laparoscopic versus open hepatectomy for liver tumours: a case control study. *Hong Kong Med J*. 2007;13:442-8.
6. Lai EC, Tang CN, Ha JP, Li MK. Laparoscopic liver resection for hepatocellular carcinoma: ten-year experience in a single center. *Arch Surg*. 2009;144:143-7.
7. Cheung TT, Poon RT, Yuen WK, Chok KS, Jenkins CR, Chan SC, Fan ST, Lo CM. Long-term survival analysis of pure laparoscopic versus open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a single-center experience. *Ann Surg*. 2013;257:506-11.



8. Mizuguchi T, Kawamoto M, Meguro M, Shibata T, Nakamura Y, Kimura Y, Furuhashi T, Sonoda T, Hirata K. Laparoscopic hepatectomy: a systematic review, meta-analysis, and power analysis. *Surg Today*. 2011;41:39-47.

9. Nguyen KT, Marsh JW, Tsung A, Steel JJ, Gamblin TC, Geller DA. Comparative benefits of laparoscopic vs open hepatic resection: a critical appraisal. *Arch Surg*. 2011;146:348-56.

10. Mirnezami R, Mirnezami AH, Chandrakumaran K, Abu Hilal M, Pearce NW, Primrose JN, Sutcliffe RP. HPB (Oxford). Short- and long-term outcomes after laparoscopic and open hepatic resection: systematic review and meta-analysis. 2011;13:295-308.

11. Hwang DW, Han HS, Yoon YS, et al. Laparoscopic major liver resection in Korea: a multicenter study. *J Hepatobiliary Pancreat Sci*. 2013;20:125-30.

12. Lai EC, Tang CN, Li MK. Robot-assisted laparoscopic hemi-hepatectomy: technique and surgical outcomes. *Int J Surg*. 2012;10:11-5

13. Lai EC, Tang CN, Yang GP, Li MK. Approach to manage the complications of choledochoduodenostomy: robot-assisted laparoscopic Roux-en-Y hepaticojejunostomy. *Surg Laparosc Endosc Percutan Tech*. 2011;21:e228-31.

14. Lai EC, Tang CN, Yang GP, Li MK. Multimodality laparoscopic liver resection for hepatic malignancy—from conventional total laparoscopic approach to robot-assisted laparoscopic approach. *Int J Surg*. 2011;9:324-8.

15. Lai EC, Yang GP, Tang CN. Robot-assisted laparoscopic liver resection for hepatocellular carcinoma: short-term outcome. *Am J Surg*. 2013;205:697-702.

16. Giulianotti PC, Coratti A, Sbrana F, Addeo P, Bianco FM, Buchs NC, Annechiarico M, Benedetti E. Robotic liver surgery: results for 70 resections. *Surgery*. 2011;149:29-39.

MCHK CME Programme Self-assessment Questions

Please read the article entitled "The Current Status of Minimally Invasive Liver Surgery" by Dr. Eric CH LAI, Prof. Michael KW LI, BBS and Dr. Chung-ngai TANG and complete the following self-assessment questions. Participants in the MCHK CME Programme will be awarded CME credit under the Programme for returning completed answer sheets via fax (2865 0345) or by mail to the Federation Secretariat on or before 30 August 2013. Answers to questions will be provided in the next issue of The Hong Kong Medical Diary.

Questions 1-10: Please answer T (true) or F (false)

- The best indication for laparoscopic liver resection is in patients with solitary lesions (≤5cm) located in peripheral liver segments.
- A huge liver tumour with 20 cm in size is an acceptable indication for laparoscopic liver resection.
- Malignant pathologies are contraindications for any laparoscopic liver resection.
- Studies showed that in selected patients, laparoscopic liver resection can reduce operative blood loss and results in less postoperative analgesic drug consumption, and shorter hospital stay.
- Laparoscopic left lateral sectionectomy should be considered as a standard practice.
- Laparoscopic major hepatectomy is a popularised technique of liver resection.
- The costs of robotic approach of liver resection is its main disadvantage.
- Robotic surgery emphasises teamwork between two experienced surgeons.
- The robotic system has the special features of precision, steadiness, and dexterity.
- The robotic system retains tactile feedback during operation.

ANSWER SHEET FOR AUGUST 2013

Please return the completed answer sheet to the Federation Secretariat on or before 30 August 2013 for documentation. 1 CME point will be awarded for answering the MCHK CME programme (for non-specialists) self-assessment questions.

The Current Status of Minimally Invasive Liver Surgery

Dr. Eric CH LAI

MBChB(CUHK), MRCS(Edin), FRACS, FCSHK, FHKAM(Surg) Consultant, Department of Surgery, Pamela Youde Nethersole Eastern Hospital

Dr. Chung-ngai TANG

MBBS(HK), FRCS(Edin), FCSHK, FHKAM(Surgery) Consultant & Chief of Service, Department of Surgery, Pamela Youde Nethersole Eastern Hospital

Prof. Michael KW LI, BBS

MBBS(Lond), MRCS(Eng), LRCP(Lond), FRCS(Eng), FRCS(Edin), FCSHK, FHKAM(Surgery) Professor of Surgery, University College London, United Kingdom Honorary Consultant in General Surgery, Director of Minimally Invasive & Robotic Surgery Development, Hong Kong Sanatorium & Hospital, Hong Kong Consultant Surgeon in Department of Surgery, Advisor of Minimal Access Surgery Training Centre, Pamela Youde Nethersole Eastern Hospital, Hong Kong

1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] 6 [ ] 7 [ ] 8 [ ] 9 [ ] 10 [ ]

Name (block letters): \_\_\_\_\_ HKMA No.: \_\_\_\_\_ CDSHK No.: \_\_\_\_\_

HKID No.: \_\_\_\_ - \_\_\_\_ - \_\_\_\_ X X (X) HKDU No.: \_\_\_\_\_ HKAM No.: \_\_\_\_\_

Contact Tel No.: \_\_\_\_\_

Answers to July 2013 Issue

Clinical Applications of Musculoskeletal Ultrasonography in Physical Medicine and Rehabilitation

1. F      2. F      3. T      4. F      5. T      6. T      7. T      8. F      9. F      10. F

# daflon<sup>®</sup> 500mg

**Micronized** purified flavonoid fraction

The first and unique venoactive drug<sup>1</sup>  
with

-  A rapid and superior efficacy in relieving venous pain<sup>2-4</sup>
-  A vein-specific anti-inflammatory action<sup>5,6</sup>
-  A high-quality micronized formulation<sup>7,8</sup>

*The best chance to relieve your patients*



## Chronic Venous Disease



**2 tablets daily**

1 - Nicolaidis A, Perrin M. The updated guidelines held in Cyprus on 'The management of chronic venous disorders of the lower limbs' and the place of venoactive drugs. Presented at the Union Internationale de Phlébologie Congress; September 8-13, 2013; Boston, USA. 2 - Amiel R, Barbe M. *Phlebology*. 1992;7(suppl 2):41-44. 3 - Cospite M, Dominici A. *Int Angiol*. 1989;8(suppl 4): 61-65. 4 - Allaert FA. *Int Angiol*. 2012;31(4):310-315. 5 - Vital A, Carles D, Serise JM, Boisseau MR. Evidence for unmyelinated C fibers and inflammatory cells in human varicose saphenous veins. *Int J Angiol*. 2010; 19:73-77. 6 - Pascarella L. Essentials of Daflon 500 mg: from early valve protection to long-term benefits in the management of chronic venous disease. *Curr Pharma Des*. 2007;13:431-444. 7 - Garner RC, Garner JV, Gregory S, et al. Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting. *J Pharm Sci*. 2002;91:32-40. 8 - Agus G.B. Conservative treatment of chronic venous disease: the Italian experience. *Phlebology*. 2013;20(2):101-112. 9 - Paysant J, Sansilvestri-Morel P, Bouskela E, Verbeuren TJ. Different flavonoids present in the micronized purified flavonoid fraction (Daflon 500 mg) contribute to its anti-hyperpermeability in the hamster cheek pouch microcirculation. *Int Angiol*. 2008;27:81-85.

**Presentation and composition:** Micronized, purified flavonoid fraction 500 mg: diosmin 450 mg; hesperidin 50 mg. **Therapeutic properties:** Vascular protector and venotonic. Daflon 500 mg acts on the return vascular system: it reduces venous distensibility and venous stasis; in the microcirculation, it normalizes capillary permeability and reinforces capillary resistance. **Pharmacokinetics:** Micronization of Daflon 500 mg increases its gastrointestinal absorption compared to nonmicronized diosmin (urinary excretion 57.9% vs 32.7%). **Therapeutic indications:** Treatment of organic and idiopathic chronic venous insufficiency of the lower limbs with the following symptoms: heavy legs; pain; nocturnal cramps. Treatment of hemorrhoids and acute hemorrhoidal attacks. **Side effects:** Some cases of minor gastrointestinal and autonomic disorders have been reported, but these never required cessation of treatment. **Drug interactions:** None. **Precautions:** Pregnancy: experimental studies in animals have not demonstrated any teratogenic effects, and no harmful effects have been reported in man to date. Lactation: in the absence of data concerning the diffusion into breast milk, breast-feeding is not recommended during treatment. **Contraindications:** None. **Dosage and administration:** In venous disease: 2 tablets daily. In acute hemorrhoidal attacks: the dosage can be increased to up to 6 tablets daily.

As prescribing information may vary from country to country, please refer to the complete data sheet supplied in your country.

Les Laboratoires Servier - 45520 Gidy - France. Correspondent: Servier International 50, rue Carnot - 92284 Suresnes Cedex - France. Website: [www.servier.com](http://www.servier.com)

# Video-assisted Thoracoscopic Surgery Today

## Dr. Yuk-ping TAI

MBBS (Lond), FRCS(Ed), FCSHK, FHKAM

Consultant surgeon (part time), Pamela Youde Nethersole Eastern Hospital  
Private Practice



Dr. Yuk-ping TAI

Thoracotomy is one of the most painful incisions in surgical procedures, and its associated complications such as pneumonia are well known. Video-assisted thoracoscopic surgery (VATS) offers the benefits of a minimally invasive approach with reduced pain and complications.<sup>1,2</sup>

In fact thoracoscopy is not new. Back in 1910, Professor HC Jacobeus had already performed thorascopies for his patients, mainly for diagnostic purposes. There had been little progress over nearly one century. It was not until the early 1990s when there was a rapid development in laparoscopic surgery with improved optics and instruments, that VATS took off as well with great enthusiasm. Nowadays, many thoracic procedures can be performed using the VATS approach.

## Hyperhidrosis

Sweaty palms could be quite distressing to some patients. Unfortunately in the past, the traditional open approach, either supraclavicular or transaxillary, was associated with significant risks such as phrenic nerve injury and lung injury in addition to a large wound. Not surprisingly, physicians were reluctant to refer patients for sympathectomy in the past. With VATS, the procedure can be performed via 2 to 3mm incisions and the patients are often discharged on the same day. The result is extremely good with nearly 100% success rate and minimal risks.<sup>3,4,5</sup> VAT sympathectomy is now the choice of permanent treatment for patients with disturbing hyperhidrosis.

## Pneumothorax and pleural effusion

Another thoracic condition that is benefited greatly from VATS is spontaneous pneumothorax. A very clear thoracoscopic view enables identification of bullae which are often the cause of the air leak. The bullae can be easily excised with an endo-stapler or ligated with sutures. A thorough mechanical pleural abrasion ensures sound pleurodesis. The patient can be discharged three to five days after operation. Recurrent rate is around 5%.<sup>6,7</sup> For those elderly patients with secondary spontaneous pneumothorax, VAT pleurodesis can be performed under local anaesthesia with talc powder. The result is equally good.<sup>8</sup> VAT talc pleurodesis is also indicated for those patients suffering from malignant pleural effusion and for recurrent pleural effusion from other causes such as peritoneal dialysis.<sup>9</sup>

## Lung cancers

For lung cancers, VAT lobectomy eliminates the

complications associated with a thoracotomy. Post operative pain is minimal and the patient can be discharged 5 to 7 days after the operation. Studies have shown that for early stage cancers VATS offers similar oncological clearance as traditional open lobectomy with comparable survival rates.<sup>1</sup>

## Indeterminate lung nodules

With increased health awareness and more exhaustive pre-operative investigations such as CT, MRI and PET scan, more abnormalities are being picked up in asymptomatic patients. In most cases, the physician is obliged to do further investigations to find out the nature of these lesions. CT guided fine needle aspiration (FNA) cytology offers the best answer if the lesion is big enough for aspiration and locates in a position amenable to percutaneous biopsy. However, FNA might not be successful or conclusive. VAT offers a clear examination of the pleural cavity and the lung lobes, and excision of the nodule provides a specimen for a definitive histological diagnosis.<sup>10</sup>

## Other thoracic conditions

Other thoracic procedures that are amenable to VATS include thymectomy for myasthenia gravis and thymoma, excision or biopsy of mediastinal tumours, decortication for early empyema thoracis and diagnosis for pleural effusion of unknown causes. The advantages of minimally invasive surgery in terms of less post-operative pain and faster recovery are well seen in VATS for these conditions.<sup>11,12</sup>

## Conclusion

VATS has much developed and matured over the last 20 years, and many thoracic operations can now be safely performed with improved clinical outcomes.



Figure 1. Theatre setup for a VAT operation.




Figure 2. (a) wet palms (b) same patient's palms two weeks after VAT sympathectomy. Note completely dry hands after surgery.



Figure 3. Lung bulla in a patient with spontaneous pneumothorax



Figure 4. Thoracoscopy in a patient with pleural effusion of unknown cause. VAT clearly shows pleural metastasis as cause for the effusion

## References

1. Scott WJ, Allen MS, Darling G, Meyers B, Decker PA, Putnam JB, McKenna RW, Landreneau RJ, Jones DR, Inculet RI, Malthaner RA. Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial. *J Thorac Cardiovasc Surg.* 2010 Apr;139(4):976-81
2. Deva AK, McCaughan BC, Monaghan G, Hendel PN, Hughes CF, Thomson DS, Baird DK. Video-assisted thoracoscopy. *Aust N Z J Surg.* 1994 Oct;64(10):705-9.
3. Tai YP, Lee MWM, Li MKW. Thoracoscopic sympathectomy for palmar hyperhidrosis: Hong Kong early experience. *Hong Kong Medical Journal.* 96; 2(3): 315-8
4. Wait SD, Killory BD, Lekovic GP, Ponce FA, Kenny KJ, Dickman CA. Thoracoscopic sympathectomy for hyperhidrosis: analysis of 642 procedures with special attention to Horner's syndrome and compensatory hyperhidrosis. *Neurosurgery.* 2010 Sep;67(3):652-6;
5. Herbst F, Plas EG, Fugger R, Fritsch A. Endoscopic thoracic sympathectomy for palmar hyperhidrosis of the upper limb. A critical analysis and long-term results of 480 operations. *Ann Surg* 1994;220:86-90.
6. Chan P, Clarke P, Daniel FJ, Knight SR, Seevanayagam S. Efficacy study of video-assisted thoracoscopic surgery pleurodesis for spontaneous pneumothorax. *Ann Thorac Surg.* 2001 Feb;71(2):452-4.
7. Gossot D, Galetta D, Stern JB, Debrosse D, Caliendo R, Girard P, Grunenwald D. Results of thoracoscopic pleural abrasion for primary spontaneous pneumothorax. *Surg Endosc.* 2004 Mar;18(3):466-71
8. Ramos-Izquierdo R, Moya J, Macia I, Rivas F, Ureña A, Rosado G, Escobar I, Saumench J, Cabrera A, Delgado MA, Villalonga R. Treatment of primary spontaneous pneumothorax by videothoracoscopic talc pleurodesis under local anesthesia: a review of 133 procedures. *Surg Endosc.* 2010 May;24(5):984-7
9. Mak SK, Nyunt K, Wong PN, Lo KY, Tong GM, Tai YP, Wong AK. Long-term follow-up of thoracoscopic pleurodesis for hydrothorax complicating peritoneal dialysis. *Ann Thorac Surg.* 2002 Jul;74(1):218-21.
10. Mack MJ, Hazelrigg SR, Landreneau RJ, Acuff TE. Thoracoscopy for the diagnosis of the indeterminate solitary pulmonary nodule. *Ann Thorac Surg.* 1993 Oct;56(4):825-30
11. Toker A, Tanju S, Ziyade S et al. Early outcomes of video-assisted thoracoscopic resection of thymus in 181 patients with myasthenia gravis: who are the candidates for the next morning discharge? *Interact Cardiovasc Thorac Surg.* 2009 Dec;9(6):995-8.
12. Venissac N, Leo F, Hofman P et al. Mediastinal neurogenic tumors and video-assisted thoracoscopy: always the right choice? *Surg Laparosc Endosc Percutan Tech.* 2004 Feb;14(1):20-2

## MIS Upper GI

**Dr. Frances CHEUNG**

MBChB(CUHK), MRCS(Ed), FRCS Ed(Gen), FHKAM(Surgery)

Consultant, Department of Surgery, Pamela Youde Nethersole Eastern Hospital

Upper Gastrointestinal surgery has undergone revolutionary changes in the past few decades. Changing epidemiology, medical regimens to treat peptic ulcer disease, development of laparoscopic, endoscopic and robotic instruments and skills made minimal access surgery an important role in managing many benign and malignant diseases of the upper gastrointestinal tract.

### MIS in peptic ulcer disease

Identification and eradication of *Helicobacter pylori* and the high efficacy of proton pump inhibitors have resulted in successful medical therapy of peptic ulcer disease in the vast majority of patients. Definitive ulcer surgery is rarely required now. Surgery treatment is reserved for complications such as massive uncontrolled bleeding, perforation or obstruction. Though open surgery is still the mainstay of treatment for massive bleeding uncontrolled by endoscopy, the majority of peptic ulcer perforations are amenable for laparoscopic repair. Patients with perforated peptic ulcers usually present with acute abdominal pain and peritoneal signs. Most of them suffer from small perforations (less than 1cm) and present early. Laparoscopic peritoneal irrigation and omental suture repair of the perforation is technically feasible in these patients. One randomised controlled trial (n=130) showed laparoscopic repair of perforated peptic ulcers was associated with a shorter operating time, less postoperative pain, reduced pulmonary complications, shorter postoperative hospital stay and earlier return to normal daily activities compared with conventional open surgery<sup>1</sup>. The Cochrane Systematic Review showed laparoscopic surgeries offer similar clinical results as open ones<sup>2</sup> while another systematic review showed laparoscopic repairs benefit low risk patients<sup>3</sup>. Provided the necessary expertise is available, laparoscopic repair is considered for most patients with perforated peptic ulcers.

Gastric outlet obstruction from peptic ulcers may be due to oedema from the ulcer or scar from refractory peptic ulcer disease. The former usually resolves with medications including proton pump inhibitors and *Helicobacter pylori* eradication regimen. The latter often requires surgery or endoscopic dilatation. The result of endoscopic balloon dilatation is variable depending on the size of the balloon used, the *Helicobacter* status, and not without risk of perforation<sup>4</sup>. In patients with general condition feasible for general anaesthesia, minimally invasive laparoscopic techniques (truncal vagotomy and gastrojejunostomy) have been developed to be safe and effective procedures with reduced postoperative recovery time compared with open surgery<sup>5</sup>.

### MIS in neoplastic lesions

With advances in optics, energy source and stapling devices, safe resection of benign lesions in oesophagus and stomach with minimally invasive surgery have been proved in various series. Thoracoscopic enucleation of oesophageal leiomyoma, and wedge resection of gastric stromal tumour (Figure 1) have been proved to be both safe and feasible with reduced access trauma<sup>6</sup>.



Figure 1. Endoscopic assisted laparoscopic intragastric resection of gastrointestinal stromal tumor

Surgeries for cancers of the oesophagus and stomach entail en-bloc resections with lymphadenectomy. Screening diagnosed cancer in early stage. Surgical pathological correlations showed that early cancers of oesophagus and stomach rarely metastasise to regional lymph nodes when certain criteria are satisfied. Therefore, it is oncologically safe to resect these early tumours endoscopically by EMR (endoscopic mucosal resection) or ESD (endoscopic submucosal dissection) techniques (Table 1 and Table 2). Follow up studies have confirmed the long term results of endoscopic resection of early cancers. Local recurrence from a large retrospective study with 472 patients was 1% and overall 5 years survival was 83% (none due to gastric cancer)<sup>7</sup>. For patients not fulfilling the criteria for endoscopic resection, surgery is the main therapeutic modality. Less extensive lymphatic dissection is required in these early tumours. Meta-analysis have reported short term efficacy of decreased wound pain, length of hospital stay, blood loss and a trend towards reduced complications, while the recurrence and survival rates were similar to open gastrectomy<sup>8</sup>. The Japanese Laparoscopic Surgery Study



Group reported the oncologic outcomes of 1294 patients who had undergone laparoscopic gastrectomy for early gastric cancer, the 5-year disease-free survival rates were 99.8%, 98.7% and 85.7% for stage 1A, 1B and II disease respectively<sup>9</sup>. In Korea, multicentre data showed similar good results with disease recurrence of 1.6% for early gastric cancer and 13.4% for advanced gastric cancer in a 41-month follow up<sup>10</sup>. Currently, the Gastric Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG 0912) and the KLASS group (KLASS 01) are conducting multi-institutional prospective randomised controlled phase III trials to compare laparoscopic gastrectomy with open gastrectomy. A separate phase III study for evaluating the feasibility of laparoscopic surgery in advanced gastric cancer is also underway in Korea (KLASS 02). Although there is still some controversies between the Western and Eastern studies on the efficacy for D2 lymph node dissection, it is the accepted standard procedure for advanced gastric cancer in Korea, Japan and many Eastern and Western centres. With advances in technique and experience of surgeons, laparoscopic-assisted gastrectomy has been applied for advanced gastric cancers. Small studies have reported comparable long term outcomes to open operation<sup>11</sup> while large scale multicentre randomised controlled trial is awaited.

**Table 1. Indications and contraindications of endoscopic mucosal resection for early oesophageal neoplasia**


<b>Absolute indications</b>
HGIN (BE)
T1 m1-m3
No risk factors
<ul style="list-style-type: none"> <li>Lymphatic invasion (L1)</li> <li>Venous infiltration (V1)</li> <li>Poorly differentiated Carcinoma (G3)</li> <li>Macroscopic elevated or flat</li> </ul>
<b>Intermediate indications</b>
Tumour size >20 mm
Multifocal cancer
T1 sm1 infiltration
No risk factors
<b>Contraindications</b>
T1 sm2 infiltration or deeper
T1 sm1 cancer with one risk factor
Ulcerative lesion
Data from Pech O, May A, Rabenstein T, et al. Endoscopic resection of early oesophageal cancer. Gut 2007;56:1625-34.

**Table 2. Indications for endoscopic resection for gastric neoplasm**

Mucosal tumour (intestinal type), no ulcer, any size
Mucosal tumour (intestinal type) ulcer <3cm
Submucosal tumour (sm1) intestinal type, <3cm
From Gotoda et al. Gastric Cancer 2002

Cancer of oesophagus is the ninth most common malignancy worldwide and sixth on cancer mortality. Superficial oesophageal neoplasms involving the mucosa or superficial submucosa has minimal risk of lymphatic spread and carry significantly better survivals. Endoscopic resection is indicated in those with M1, 2 and M3 and SM1 lesions without lymphovascular permeation. More advanced lesions require surgical resection with or without pre-operative chemoradiotherapy. Conventional open oesophagectomy has significant access trauma. MIS techniques have been employed in an attempt to

reduce access trauma (Figure 2). It also has benefits of magnification of view; potentially making more precise dissection feasible, though with lack of tactile sensation, dissection around bulky tumour close to vital organs such as the aorta and trachea can be more difficult and potentially more dangerous. The available literature on minimally invasive oesophagectomy (MIE), is heterogeneous, with different techniques including various combinations of thoracoscopy, laparoscopy, mediastinoscopy, and laparoscopic assisted (with minilaparotomy or hand-port devices) or thoracoscopic-assisted methods (with minithoracotomy). Most of them are case series, several with comparison to historical data. The place of MIE is evolving. Pooled data have shown it to be similar to open surgery in perioperative mortality and morbidity. There may be associated less blood loss, less postoperative pain, and shorter length of stay in the intensive care unit and hospital while survivals were similar<sup>12-14</sup>. MIE is a complex operation with a definite learning curve which often requires centres with a high volume and experience in open surgery to investigate its potential benefits, where a randomised controlled trial is underway to explore its potential.



**Figure 2. Thoracoscopic-assisted esophagectomy**

## MIS in functional and motility disorder

Anti-reflux surgery is an effective treatment for patients with GERD refractory to medical therapy, who have symptom recurrence when medicine is withdrawn<sup>15</sup>. Laparoscopic Nissen fundoplication is the most commonly performed procedure, it reduces the access morbidity of upper midline laparotomy incision<sup>16</sup>. Good to excellent long-term results are reported in 80-93% of patients<sup>17, 18</sup>. Achalasia is a primary motor disorder of the oesophagus characterised by a lack of relaxation of the lower oesophageal sphincter and ineffective oesophageal body peristalsis. Treatment modalities aim to reduce the high muscle tone of the lower oesophageal sphincter. Since its introduction in 1991, laparoscopic cardiomyotomy has become the first-line therapy to treat achalasia recently. It offers the advantage of good exposure of the lower oesophagus and cardia, with good relief of dysphagia in 90% with low morbidity, compared favourably to endoscopic and other approaches<sup>19</sup>.

## Robotic Surgery

Although laparoscopy has changed the surgical approach of many upper GI conditions, it has several limitations including a 2-dimensional vision, limited manipulation,

ergonomic discomfort and increase of physiologic tremor. Robotic technology, with its computerised mechanical interface and seven degrees of freedom, has overcome many of these drawbacks. Several clinical trials have shown that the robotic system can enhance the skill of surgeons in performing difficult dissections and suturing techniques (Figure 3). In a prospective study comparing 37 patients who underwent laparoscopic and 24 patients with robotic Heller myotomy, 3 oesophageal perforations (8%) were recorded in the laparoscopic group while none in the robotic group<sup>20</sup>. Robotics has also been reported in performing lymphatic dissection in gastric and oesophageal cancer surgery<sup>21, 22</sup> and endoscopic submucosal dissection in early gastric cancers<sup>23</sup>.



Figure 3. Robotic Heller cardiomyotomy

## Conclusion

Development of endoscopic, laparoscopic and robotic instruments and techniques and integrating them has revolutionised traditional upper GI surgery. Their role is expected to be ever increasing with further technical development and evidence to support their benefits.

## References

1. Siu WT, Leong HT, Law BK, et al. Laparoscopic repair for perforated peptic ulcer: a randomized controlled trial. *Ann Surg* 2002;235(3):313-9.
2. Sanabria AE, Morales CH, Villegas MI. Laparoscopic repair for perforated peptic ulcer disease. *Cochrane Database Syst. Rev.* 2005;(4):CD004778.
3. Lunevicius R, Morkevicius M. Systematic review comparing laparoscopic and open repair for perforated peptic ulcer. *Br J Surg* 2005;92(10):1195-207.
4. Cherian PT, Cherian S, Singh P. Long-term followup of patients with gastric outlet obstruction related to peptic ulcer disease treated with endoscopic balloon dilatation and drug therapy. *Gastrointest Endosc* 2007;66(3):491-7.
5. Palanivelu C, Jani K, Rajan PS, et al. Laparoscopic management of acid peptic disease. *Surg Laparosc Endosc Percutan Tech* 2006;16(5):312-6.
6. Novitsky YW, Kercher KW, Sing RF. Long-term outcomes of Laparoscopic Resection of Gastric Gastrointestinal Stromal Tumors. *Ann Surg* 2006;243(6):738-747.
7. Kosaka T, Endo M, Toya Y. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: A single-center retrospective study. *Dig Endosc* 2013.
8. Memon MA, Khan S, Yunus RM. Meta-analysis of laparoscopic and open distal gastrectomy for gastric carcinoma. *Surg Endosc* 2008;22:1781-1789.
9. Kitano S, Shiraishi N, Uyama I. Japanese Laparoscopic Surgery Study Group. A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan. *Ann Surg* 2007;245(1):68-72.
10. Song J, Lee HJ, Cho GS. Recurrence following laparoscopy-assisted gastrectomy for gastric cancer: a multicenter retrospective analysis of 1,417 patients. *Ann Surg Oncol.* 2010;17:1777-1786.
11. Zhao XF, Jeong O, Jung MR, Ryu SY. A propensity score-matched case-control comparative study of laparoscopic and open extended (D2) lymph node dissection for distal gastric carcinoma. *Surg Endosc.* 2013.
12. Biere SSA, Cuesta MA, Van Del Peet DL. Minimally invasive versus open esophagectomy for cancer: a systematic review and meta-analysis. *Minerva Chir.* 2009;64:121-33.
13. Sgourakis G, Gockel I, Radtke A, et al. Minimally invasive versus open esophagectomy: metaanalysis of outcomes. *Dig Dis Sci.* 2010;55:3031-40.
14. Nagpal K, Ahmed K, Vats A, Yakoub DI. Is minimally invasive surgery beneficial in the management of esophageal cancer? A meta-analysis. *Surg Endosc.* 2010;24:1621-9.
15. Spechler SJ. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. *N Engl J Med* 1992;326:786-92.
16. Eshraghi N, Farahmand M, Soot SJ. Comparison of outcomes of open versus laparoscopic Nissen fundoplication performed in a single practice. *Am J Surg* 1998;175:371-4.
17. Macintyre IM, Goulbourne IA. Long-term results after Nissen fundoplication: a 5-15-year review. *J R Coll Surg Edinb* 1990;35:159-62.
18. Morgenthal CB, Shane MD, Stival A. The durability of laparoscopic Nissen fundoplication: 11-year outcomes. *J Gastrointest Surg* 2007;11:693-700.
19. Campos GM, Vittinghoff E, Rabl C. Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis. *Ann Surg* 2009;249:45-57.
20. Huffmann LC, Pandalai PK, Boulton BJ. Robotic Heller myotomy: a safe operation with higher postoperative quality-of-life indices. *Surgery* 2007;142:613-618:discussion 618-620.
21. Song J, Sung J, Wook H. Robot-assisted gastrectomy with lymph node dissection for gastric cancer: lessons learned from an initial 100 consecutive procedures. *Ann Surg* 2009;249:927-932.
22. Puntambekar SP, Rayate N, Joshi S. Robotic transthoracic esophagectomy in the prone position: Experience with 32 patients with esophageal cancer. *J Thorac Cardiovasc Surg*; 2011;142(5):1283-4.
23. Phee SJ, Reddy N, Chiu PW. Robot-assisted endoscopic submucosal dissection is effective in treating patients with early-stage gastric neoplasia. *Clin Gastroenterol Hepatol*; 2012;10(10):1117-21.

## Classified Advertisement

Vacancies

Commencement  
of Practice

Rental /  
For Sale

Please contact the Federation Secretariat at 2527 8898 for placement of classified advertisement.



MENARINI



## NSAIDs HAVE ALSO EVOLVED

Ketesse® is an innovative, next-generation NSAID. As a pure enantiomer, it offers high analgesic efficacy at low doses,\* while its tromethamine salt formulation means it is absorbed fast,† resulting in rapid pain relief in as little as 15 minutes.‡ With an excellent tolerability profile compared to other NSAIDs,§ Ketesse® is an evolution in NSAID choice.

References: 1. Ketesse® product monograph (oral). 2. Begán JF, Amoz JSL, Valencia E, Santamaría J, Egudani I, Horro M, Forns M, Zapata A, Ariges R, Madroñe D. Clinical comparison of dexketoprofen trometamol and diclofenac in postoperative dental pain. J Clin Pharmacol 1996;38(12 Suppl):655-665. 3. Morisco JL, Ferriz M, Navarro FJ, Martínez FJ, Belmont J, Schwederski D, Martín A, Esteban M, Egudani I, Zapata A, Horro M, Torres F, Ariges R, Madroñe D. A multicentre, randomised, double-blind study to compare the efficacy and tolerability of dexketoprofen trometamol versus diclofenac in the symptomatic treatment of knee osteoarthritis. Clin Drug Invest 2000;19(4):247-56. 4. Zippel H and Wajszyn A. A multicentre, randomised, double-blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain. Clin Drug Invest 2007;27(9):533-42. 5. Barbaño MJ, Gole L, Ariges R, Tost D, Moros C, Antolujan RM, Garcia ML, Madroñe D. Pharmacokinetics of dexketoprofen trometamol in healthy volunteers after single and repeated oral doses. J Clin Pharmacol 1996;38(12 Suppl):635-635. 6. Lemaire P, Kapadia Y, Hurevitch J. Randomised controlled trial of the extent of analgesic efficacy of dexketoprofen and diclofenac in lower limb injury. Emerg Med J 2003;29(6):511-3. 7. Carter X, Ross J, Torres F. Postmarketing cohort study to assess the safety profile of oral dexketoprofen trometamol for mild to moderate acute pain treatment in primary care. Meth Find Exp Clin Pharmacol 2009;31(6):533-40. 8. Moore RA and Barden J. Systematic review of dexketoprofen in acute and chronic pain. BMC Clin Pharmacol 2008;8:11.

**Ketesse®**  
Dexketoprofen trometamol

EFFECTIVE · FAST · TRUSTED

Abbreviated Prescribing Information

**KETESSE® 25 mg Tablets**

**Indication:** Mild to moderate pain, such as muscular pain, painful periods (dysmenorrhea), lumbache. **Dosage and Administration:** 25 mg (1 tab) every 6 hrs. For elderly, and patients with kidney or liver problems: start with total daily dose of no more than 50 mg (2 tabs). Max. 75 mg (3 tabs)/day. **Side effects:** Nausea and/or vomiting, abdominal pain, diarrhea, digestive problems (dyspepsia). **Precautions:** Caution in patients with heart problems, previous stroke, who might be at risk of these conditions. Do not use during pregnancy or when breast feeding. Not to be given to children or adolescents. Caution in the elderly and in patients with kidney or liver problems. **Contraindications:** Hypersensitivity to dexketoprofen, aspirin, or other NSAIDs. Patients with history of asthma attacks, acute allergic rhinitis, nasal polyps, ulcers, angioedema or wheezing in the chest, after taking aspirin or other NSAIDs. Patients with history of peptic ulcer, dyspepsia, or Crohn's disease or ulcerative colitis. Bleeding from the stomach or bowel in the past. Severe heart failure; moderate to severe kidney disorders; severely impaired liver function; Bleeding disorder; Blood clotting disorder; Pregnant or breast feeding.

**KETESSE® 50 mg/2 ml**

**Indication:** Acute moderate to severe pain, such as post-operative pain, renal colic (severe kidney pain) and lower back pain. **Dosage and Administration:** IM: 2ml by slow injection deep into the muscle. IV infuser: Dilute 2 ml as directed. Diluted solution administered as slow IV infusion over 10-30 min. IV bolus: 2 ml in a slow IV bolus over no less than 15 seconds. **Side effects:** Nausea, vomiting, heartburn, stomach pain, diarrhea and pain at the injection site. **Precautions:** Caution in patients with heart problems, previous stroke, who might be at risk of these conditions. Do not use during pregnancy or when breast feeding. Not to be given to children. Caution in the elderly and in patients with kidney or liver problems. **Contraindications:** Contraindicated for neuraxial (intrathecal or epidural) administration due to its ethereal content. Hypersensitivity to dexketoprofen, aspirin, or other NSAIDs. Patients with history of asthma attacks, acute allergic rhinitis, nasal polyps, ulcers, angioedema or wheezing in the chest, after taking aspirin or other NSAIDs. Patients with history of peptic ulcer, dyspepsia, or Crohn's disease or ulcerative colitis. Bleeding from the stomach or bowel in the past. Severe heart failure; moderate to severe kidney disorders; severely impaired liver function; Bleeding disorder; Blood clotting disorder; Pregnant or breast feeding.

Please refer to full prescribing information for further information.

## MIS - Future is Here

### Dr. Hester YS CHEUNG

MB, ChB, FRACS, FHKAM

Consultant, Department of Surgery, Pamela Youde Nethersole Eastern Hospital



Dr. Hester YS CHEUNG

The development of minimally invasive surgery (MIS) in colorectal diseases began with the first report of laparoscopic assisted colectomy in 1991. There is now a wealth of evidence indicating the laparoscopic approach confers definite short term benefits to patients<sup>2,3</sup>. Even for colorectal cancer, a common malignant condition worldwide, evidence in the literature demonstrates comparable oncological outcomes as the open approach<sup>2</sup>. The following highlights the latest development in MIS for colorectal diseases.

### MIS for rectal cancer

The development of MIS for rectal cancer lagged behind that of colon cancer before the turn of the century. As dissection deep down in the pelvis is technically demanding, early reports on laparoscopic rectal cancer surgery were dominated by high anterior resection (i.e. resection of tumours around the rectosigmoid junction) and sphincter-ablating resection (i.e. abdomino-perineal resection)<sup>4-6</sup>; in the latter case the lateral or circumferential margin is usually dictated by the perineal surgeon rather than the laparoscopic surgeon. Progress in technology and skills as well as accumulation of experience and confidence, however, have finally led to the extension of MIS techniques to distal rectal cancers with sphincter preservation<sup>7</sup>. Although the number of randomised studies is still limited, the available evidence from large prospective series demonstrates its safety in experienced hands and an oncological clearance comparable to that of the open counterpart<sup>8-12</sup>. In fact, in the last decade, MIS techniques have been gradually incorporated into the clinical pathway of rectal cancer management; not only laparoscopic distal rectal cancers with sphincter preservation could now be safely performed, but investigators have also shown that MIS in patients with prior neoadjuvant chemo-irradiation is safe and carries similar short term benefits as in patients without chemo-irradiation<sup>13</sup>. Even for tumours within 5cm of the anal verge, successful sphincter-preserving excisions have been described using a combined laparoscopic and transanal technique<sup>14</sup>.

### MIS in Obstructive Colorectal Tumours

Like other advanced laparoscopic procedures, laparoscopic colectomy was initially practised in elective cases. The presence of intestinal obstruction, a common acute surgical emergency, was generally considered as a contraindication for MIS owing to limited access as a result of distended bowel. With the advent of self-expanding metallic stent (SEMS)<sup>15</sup>, laparoscopic

colectomy could be performed after endoluminal stenting. This 'endo-laparoscopic' approach allows patients to enjoy the full benefits of MIS, obviating the need of emergency laparotomy and thus stoma creation<sup>16</sup>. Moreover, the approach does not have any deleterious effect on long term oncological outcomes; the number of lymph nodes harvested is even better when compared with emergency surgery<sup>17</sup>.

### NOTES in Colorectal Surgery

Compared to open surgery, laparoscopic colectomy for colonic tumours has been proven to have definite short term benefits<sup>2,3</sup>. However, specimen retrieval still necessitates a mini-laparotomy which sometimes can be the cause and evil of postoperative pain as well as wound infection, compromising the benefits of minimally invasive surgery. Natural Orifice Transluminal Endoscopic Surgery (NOTES), the next wave of development in minimally invasive surgery, can help to achieve "scarless" surgery and abolish wound related complications in total. There are already a few case reports on transrectal approaches for colon resection; however, the technique is demanding and still evolving, and hence not widely available<sup>18</sup>.

Natural Orifice Specimen Extraction (NOSE) is another stepping stone towards "incisionless" surgery to reduce pain and wound related complications<sup>19</sup>. For application of NOSE in colorectal surgery, there are two common routes: through the anorectum and via the vagina. The transvaginal route, although limited to female patients, is plausible for resection and reconstruction of all colorectal segments and may show potential benefit, particularly when associated with a gynaecological procedure<sup>20</sup>. Specimen extraction via the anorectum is widely reported in a number of studies<sup>21</sup>.

Combining laparoscopic and NOSE - the 'hybrid' NOTES procedure, i.e. combining laparoscopic mobilisation, transection and anastomosis with transanal specimen retrieval, can overcome the technical hurdle in NOTES colectomy. This concept represents a major breakthrough in minimally invasive colorectal surgery<sup>19,21</sup>.

### Single Port Device in Colorectal Surgery

The recent introduction of single port access device has a great impact on MIS and NOTES. Not only surgery can now be performed through a single port via the umbilicus, but specimens can also be extracted through the umbilicus, a natural orifice, producing



“scarless surgery”. It was initially used for simple laparoscopic procedures such as appendectomy and cholecystectomy. Later on, the technique has been employed in laparoscopic colectomy. The technique can also be combined with the ‘hybrid’ NOTES procedure, in which the colon specimen was extracted through the rectum, obviating the need to extend the umbilical incision used for single port access surgery<sup>22</sup>.

## Robotic-assisted Colorectal Surgery

Robotic technology has been developed to obviate some of the limitations of conventional laparoscopic surgery; it provides a stable camera platform, enhanced dexterity, 3D imaging, more intuitive instrument manipulation, tremor elimination, and excellent ergonomics. However, little is known about the outcomes associated with robotic-assisted colectomy or how these outcomes compare with those achieved by the laparoscopic approach. Most reports evaluating robotic-assisted outcomes in colectomy have been feasibility studies<sup>23</sup>. Robotic proctectomy, on the other hand, has been studied more intensively, with early data suggesting that robotic surgery seems to enhance the pelvic dissection with a lower risk of circumferential resection margin (CRM) positivity<sup>24-26</sup> as well as significantly lower conversion rate when compared with laparoscopic approach in one recent meta-analysis<sup>27</sup>. Additionally, better recovery of urogenital function when compared with a pure laparoscopic approach in TME has been shown in one recent comparative study<sup>28</sup>.

For all these reasons, the concept of robotic colorectal surgery appears appealing and may represent the next leap in minimally invasive surgery. However, firm evidence to support widespread implementation is still awaiting, particularly in the light of cost concern. Thus, large scale studies with longer follow up are desperately warranted to assess not only the feasibility but also the surgical outcomes of the robotic system in order to justify the widespread use of surgical robot.

## Conclusion

Minimally invasive colorectal surgery has gone a long way since 1991. As we unfold the history, laparoscopic colectomy, from what initially was a highly specialised operation performed only by a small group of privileged surgeons in research or university centres, has evolved to become now a more or less standard procedure in many centres throughout the world. The development was further catalysed by progress in technology, which has brought in new elements and concepts of MIS besides laparoscopy, as well as revolutionised significantly the management of certain colorectal conditions. The indication and applicability of MIS continue to broaden.

Minimally invasive colorectal surgery will continue to flourish in the coming decades. This is reflected by the establishment of various endo-laparoscopic OR<sup>29</sup>, robotic surgery centres and training centres on laparoscopic surgery and NOTES. We believe the next generation of colorectal surgeons will be entering a new era – the era of endo-laparoscopic and robotic-assisted laparoscopic surgery. And this will be soon approaching.

## References

1. Redwine DB, Sharpe DR. Laparoscopic segmental resection of the sigmoid colon for endometriosis. *J Laparoendosc Surg* 1991; 1: 217-20.
2. Chung CC, Tsang WWC, Kwok SY, Li MKW. Laparoscopy and its current role in the management of colorectal disease. *Colorectal Disease* 2003; 5: 528-543.
3. Cheung HYS, Chung CC, Fung JTK, Wong JCH, Yau KKK, Li MKW. Laparoscopic resection for colorectal cancer in octogenarians: Results in a decade. *Dis Colon Rectum* 2007; 50: 1905-1911.
4. Leung KL, Kwok SPY, Lau WY, Meng WCS, Lam TY, Kwong KH et al. Laparoscopic-assisted resection of rectosigmoid carcinoma: immediate and medium-term results. *Arch Surg* 1997; 132: 761-4.
5. Fleshman JW, Wexner SD, Anvari M et al. Laparoscopic vs open abdomino-perineal resection for cancer. *Dis Colon Rectum* 1999; 42: 930-939.
6. Wong DCT, Chung CC, Kwok SY, Li MKW. Laparoscopic abdominoperineal resection revisited: are there any health-related benefits? A comparative study. *Techniques in Proctology*. 2006; 10: 37-41.
7. Tsang WWC, Chung CC, Kwok SY, Li MKW. Minimally invasive surgery for rectal cancer. *Surg Clin N Am* 2005; 85: 61-73.
8. Scheidbach H, Schneider C, Konradt J et al. Laparoscopic abdominoperineal resection and anterior resection with curative intent for carcinoma of rectum. *Surg Endosc* 2002; 16: 7-13.
9. Morino M, Parini U, Giraudo G et al. Laparoscopic total mesorectal excision: a consecutive series of 100 patients. *Ann Surg* 2003; 237: 335-342.
10. Leory J, Samali F, Forbes L et al. Laparoscopic total mesorectal excision (TME) for rectal cancer surgery: long-term outcomes. *Surg Endosc* 2004; 18: 281-289.
11. Tsang WWC, Chung CC, Li MKW et al. Laparoscopic sphincter-preserving total mesorectal excision with colonic J-pouch reconstruction. Five-year results. *Ann Surg* 2006; 243: 353-8.
12. Ng KH, Ng DCK, Cheung HYS, Wong JCH, Yau KKK, Chung CC, Li MKW. Laparoscopic resection for rectal cancers. Lessons learned from 579 cases. *Ann Surg* 2009; 249: 82-6.
13. Cheung HYS, Chung CC, Wong JCH, Yau KKK, Li MKW. Laparoscopic rectal cancer surgery with and without neoadjuvant chemoradiation: a comparative study. *Surg Endosc* 2009; 23: 147-52.
14. Wong DCT, Chung CC, Cheung HYS, Yau KKK, Li MKW. Simultaneous laparoscopic abdominal and transanal excision for low rectal tumours. *Surgical Practice* 2007; 11: 76-80.
15. Dohmoto M. New method-endoscopic implantation of rectal stent in palliative treatment of malignant stenosis. *Endosc Dig* 1991; 3: 1507-12.
16. Cheung HYS, Chung CC, Tsang WWC, Li MKW. Endo-laparoscopic approach versus conventional open surgery in the management of obstructing left-sided colonic carcinoma. A randomized trial. *Arch Surg* 2009; 144: 1127-32.
17. Tung KLM, Cheung HYS, Ng LWC, CC Chung, Li MKW. Endo-laparoscopic approach versus conventional open surgery in the treatment of obstructing left-sided colon cancer: Long-term follow-up of a randomized trial. *Asian J Endosc Surg* 2013; 6: 78-81.
18. Sylla P, Lacy AM. NOTES transanal rectal cancer resection using transanal endoscopic microsurgery. *Eur Surg* 2011; 43/3: 146-52.
19. Cheung HYS, Leung ALH, Ng DCK, Chung CC, Li MKW. Endo-laparoscopic colectomy without mini-laparotomy wound for left-sided colonic tumours. *World J Surg* 2009; 33: 1287-91.
20. Diana M, Perretta S, Wall J, Costantino FA, Leroy J, Demartines N, Marescaux J. Transvaginal specimen extraction in colorectal surgery: current state of the art. *Colorectal Disease* 2011; 13: 104-11.
21. Wolthuis AM, Geluwe BV, Fieuws S, Penninckx F, D’Hoore A. Laparoscopic sigmoid resection with transrectal specimen extraction: a systematic review. *Colorectal Disease* 2011; 14: 1183-990.
22. Co CS, Cheung HYS, Yau KKK, Chung CC, Li MKW. Combined single-port and endoluminal technique for laparoscopic anterior resection. *Surg Laparosc Endosc Percutan Tech* 2010; 20: 253-6.
23. Delany CP, Lynch AC, Senagore AJ, Fazio VW. Comparison of robotically performed and traditional laparoscopic colorectal surgery. *Dis Colon Rectum*. 2003; 46: 1633-9.
24. Baik SH, Kwon HY, Kim JS. Robotic versus laparoscopic low anterior resection of rectal cancer: short-term outcome of a prospective comparative study. *Ann Surg Oncol* 2009; 16: 1480-7.
25. Bianchi PP, Ceriani C, Locatelli A. robotic versus laparoscopic total mesorectal excision for rectal cancer: a comparative analysis of oncological safety and short-term outcomes. *Surg Endosc*. 2010; 24: 2888-94.
26. Park JS, Choi GS, Lim KH, Jang YS, Jun SH. Robotic-assisted versus laparoscopic surgery for low rectal cancer: case-matched analysis of short-term outcomes. *Ann Surg Oncol*. 2010; 17: 3195-202.
27. Trastulli S, Farinella E, Cirocchi R, Cavallere D, Avenia N, Sciannoneo F, Fulla N, Nova G, Boselli C. Robotic resection compared with laparoscopic rectal dissection for cancer: systematic review and meta-analysis of short-term outcome. *Colorectal Disease* 2011; 14: 134-56.
28. Kim JY, Kim NK, Lee KY, Hur H, Min BS, Kim JH. A comparative study of voiding and sexual function after total mesorectal excision with autonomic nerve preservation for rectal cancer: laparoscopic versus robotic surgery. *Annals of Surg Oncol*. 2012; 19: 2485-93.
29. Wong JCH, Yau KKK, Li MKW. Endo-lap OR: An Innovative “Minimally Invasive Operating Room: Design. *Surg Endosc* 2006; 20: 1152-6.




OLYMPUS

**OLYMPUS**

ENDOALPHA

For more information, please contact **Olympus HK and China Limited**  
L43, Office Tower, Langham Place, 8 Argyle Street, Mongkok, Kowloon, Hong Kong  
Tel : 2170 5678 Fax : 2170 5679 [www.olympus.com.hk](http://www.olympus.com.hk)

# EVIS EXERA III



**OLYMPUS**<sup>®</sup>

Your Vision, Our Future

## MIS Applications in Endocrine Pathology

**Dr. David KK TSUI**

MBChB(CUHK), FRCSEd(Gen), FCSHK, FHKAM(Surgery)  
Consultant, Department of Surgery, Pamela Youde Nethersole Eastern Hospital



Dr. David KK TSUI

### Introduction

With the development of new technology over the past decade, minimally invasive surgery (MIS) is applied in various surgical conditions including hepatobiliary, colorectal and upper gastrointestinal pathologies. In the field of endocrine-related pathology, we also find an important influence by this new technology.

### Adrenal Surgery

Since the first successful of laparoscopic adrenalectomy by Michel Gagner in 1992<sup>1</sup>, it became the standard approach to small size adrenal lesions. The most commonly performed techniques are lateral transperitoneal<sup>2,3</sup> and the posterior retroperitoneal approach<sup>4,5</sup>, with the patient in the lateral decubitus position and anterior transperitoneal<sup>3</sup> technique, with the patient in the supine position. Laparoscopic adrenalectomy is associated with less postoperative discomfort, shorter hospital stay, less morbidity, less postoperative complications and earlier return to normal activity than open approaches<sup>6-8</sup>. Meta-analysis of trials of laparoscopic transperitoneal and retroperitoneal adrenalectomy did not show any difference in clinical outcome<sup>9</sup>.

With the use of the da Vinci robotic surgery system (Intuitive Surgical, Sunnyvale, California), it facilitates the surgeons to work on a magnified view. The use of robotic instruments provides seven degrees of freedom, the robotic camera provides a three-dimensional view with good perception of depth. Several large series of robotic adrenalectomy reported the feasibility of resection of functional and nonfunctional adrenal tumours and metastases with a size limit of 10-11cm<sup>10,11</sup>. Robotic retroperitoneal adrenalectomy is an ideal approach for cortical-sparing adrenalectomy in pheochromocytoma patients for reoperation in a single adrenal gland<sup>12</sup>. The learning curve of robotic adrenalectomy is similar to laparoscopic adrenalectomy with two exceptions: longer operating time and higher causes.



Figure 1. Robotic adrenalectomy



Figure 2. Right adrenal specimen from a patient with pheochromocytoma who had undergone robotic adrenalectomy

### Parathyroid Surgery

Parathyroidectomy is the curative treatment for primary hyperparathyroidism. Traditionally, bilateral neck exploration with resection of the enlarged parathyroid glands is the 'gold standard' procedure and is associated with 95 per cent cure rate in experienced hands<sup>13</sup>. With the improvement on preoperative localisation of the gland by <sup>99m</sup>Tc-labelled sestamibi scan as well as high resolution ultrasonography, unilateral exploration has been advocated. This can be performed by conventional minimally invasive parathyroidectomy with a neck incision around 2.5cm. The use of minimally invasive video-assisted approach in parathyroidectomy (MIVAP) was reported by Gagner in 1996<sup>14</sup>. This is a revolutionised approach for the subsequent development of endoscopic neck surgery. Thereafter, MIVAP was performed under local or regional anaesthesia by Miccoli<sup>15</sup>. The advantages of MIVAP including less pain and good cosmetic result are shown in randomised studies<sup>16</sup>.



Figure 3: One week postoperative photo for a patient who had undergone conventional minimally invasive parathyroidectomy



## Thyroid Surgery

After the first report of MIVAP in 1996, Huscher et al reported video-assisted thyroidectomy in 1997<sup>17</sup>. Miccoli from Italy reported the use of small cervical wound minimally invasive video-assisted thyroidectomy (MIVAT)<sup>18</sup> in 2000. It has shown to achieve similar completeness of resection in the treatment of low and intermediate risk papillary thyroid cancer (PTC) with concomitant central neck dissection<sup>19</sup>.

With the pursuit of a more remote wound access to the neck, surgeons from the South East Asian countries describe several extracervical approaches for endoscopic thyroidectomy. These approaches involve incisions over the chest, breast, and/or axilla to hide the scars under the clothing. Ikeda et al<sup>20</sup> first described these ports in the axilla with low pressure gas insufflation for maintaining the operating space. Kang et al reported the use of skin-lifting external retractor to axilla with a chest port for medial retraction of thyroid gland<sup>21</sup>. This approach is known as the gasless transaxillary approach. It provides an excellent view of the recurrent laryngeal nerve and parathyroid glands but the exposure to the contralateral side is more difficult. The learning curve is steep because surgeons are not used to approach the thyroid gland via this access. To further increase the degree of angulations, a combined axillo-breast approach was developed by two circumareolar trocars in the breast and a single trocar in the ipsilateral axilla. This approach was later modified by the addition of another axilla port to allow better exposure of both sides. This approach is known as the bilateral axillo-breast approach (BABA)<sup>22</sup>. It has the benefit of similar exposure as in open surgery and easy access of thyroid glands bilaterally. The surgical view is similar to conventional open thyroidectomy.

With the application of the da Vinci robotic system (Intuitive Surgical, Sunnyvale, California), surgeons are allowed to operate in a three-dimensional view with seven degrees of freedom and 90 degree articulation. There are large series of robotic thyroidectomy using the transaxillary approach as well as the BABA technique. Robotic surgery is also indicated for selected malignant conditions. Kang et al<sup>23</sup> reported their experience of 200 cases of low-risk PTC robotic-assisted thyroidectomy using the gasless transaxillary approach with excellent short-term outcome. Central compartment neck dissection can be performed via this access. A multicentre study also confirmed the successful treatment of 1043 consecutive patients with low-risk PTC underwent gasless transaxillary robotic thyroidectomy<sup>24</sup>. Lee et al also reported their success in robotic BABA thyroidectomy in the treatment of low risk PTC<sup>25</sup>.



Figure 4: Thyroid specimen obtained after robotic BABA total thyroidectomy

Comparison between robotic thyroidectomy and conventional open surgery was conducted in several studies. Robotic surgery was equal to surgical completeness in the treatment of differentiated PTC by the propensity score matching<sup>26</sup>. Central neck dissection can be performed in robotic thyroidectomy. The cosmetic satisfaction and functional outcome were satisfactory in the robotic thyroidectomy group. The outcome is excellent when this procedure is performed in an experienced centre. A meta-analysis based on several non-randomised control trials published in 2012 showed that robotic thyroidectomy has no clinical benefit over endoscopic thyroidectomy and it is associated with an increased risk of complications as well as a greater amount of drainage fluid postoperatively<sup>27</sup>. The cost of robotic surgery is also significantly higher than conventional open surgery<sup>28</sup>. Therefore, surgeons should select patients based on various factors including size of the gland, location of tumour, expectation of the patients, availability of experts and equipment beforehand.



Figure 5: Day 8 postoperative photo for a patient underwent who had undergone robotic BABA thyroidectomy. The nipples are shaded. The arrows (blue and red) indicate the port sites. The specimen was extracted through the right axilla port (indicated by red arrow).



Figure 6: The same patient in Figure 5 after robotic BABA total thyroidectomy

## Conclusion

With the current advances in new technologies, we are now performing surgery by smaller incisions to improve the aesthetic outcome. Surgery can be performed under three-dimensional view in a more ergonomic way by robotic-assisted surgery. While laparoscopic adrenalectomy is regarded as the gold standard for adrenal pathology, endoscopic and robotic

thyroidectomies are still reserved in experienced centres taking care of the group of patients with a high expectation on cosmetic outcome. Further studies are required to assess the long term result of these procedures.

### References

1. Gagner M, Lacroix A, Blote E. Laparoscopic adrenalectomy in Cushing's Syndrome and pheochromocytoma. *N Engl J Medicine* 2002; 327: 1033.
2. Grubbs EG, Callender GG, Xing Y, et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve result equal to surgery plus mitotane. *Ann Surg Oncol* 2010; 17:263-270.
3. Icrad P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patients series from the French Association of Endocrine Surgeons Study Group. *World J Surg* 2001; 25: 891-897.
4. Crucitti F, Bellanone R, Ferrante A, et al. The ACC Italian Registry Study Group. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. *Surgery* 1996; 119: 161-170.
5. Walz MK, Alesina PF, Wenger FA, et al. Posterior retroperitoneoscopic adrenalectomy – result of 560 procedures in 520 patients. *Surgery* 2006; 140: 943-950.
6. Guazzoni G, Montorsi F, Boccardi A, et al. Transperitoneal laparoscopic versus open adrenalectomy for benign hyperfunctioning adrenal tumors: a comparative study. *J Urol* 1995; 153: 1597-1600.
7. Brunt LM, Doherty GM, Norton JA, et al. Laparoscopic adrenalectomy compared to open adrenalectomy for benign adrenal neoplasm. *J Am Coll Surg* 1996; 183: 1-10.
8. Thompson GB, Grant C, Van Heerde JA, et al. Laparoscopic versus open posterior adrenalectomy: a case-control study of 100 patients. *Surgery* 1997; 122: 1132-1136.
9. Nigri G, Rosman AS, Petruccianni N, et al. Meta-analysis of trials comparing laparoscopic transperitoneal and retroperitoneal adrenalectomy. *Surgery* 2013; 153: 111-119.
10. Nordenstrom E, Westerdahl J, Hallgrímsson P, et al. A prospective study of 100 robotically-assisted laparoscopic adrenalectomy. *J Robotic Surg* 2011; 5: 127-131.
11. Raman SR, Shakov E, Carnevale N, et al. Robotic adrenalectomy by an open surgeon: are outcomes different? *J Robotic Surg* 2012; 6: 207-212.
12. Asher KP, Gupta GN, Boris RS, et al. Robot-assisted laparoscopic partial adrenalectomy for pheochromocytoma: The National Cancer Institute Technique. *Eur Urol* 2011; 60: 118-124.
13. Bergenfels A, Lindblom P, Tibblin S, et al. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial. *Ann Surg* 2002; 236: 543-551.
14. Gagner M. Endoscopic subtotal parathyroidectomy in patients with primary hyperparathyroidism. *Br J Surg* 1996; 83: 875.
15. Miccoli P, Berti P, Materazzi G, et al. Results of video-assisted parathyroidectomy: single institution's six-year experience. *World J Surg* 2004; 28:1216-1218
16. Miccoli P, Bendinelli C, Berti P, et al. Video-assisted versus conventional parathyroidectomy in primary hyperparathyroidism: a prospective randomized study. *Surgery* 1999; 126: 1117-1122.
17. Huscher CS, Chiodini S, Napolitano C, et al. Endoscopic right lobectomy. *Surg Endosc* 1997; 11: 877
18. Miccoli P, Berti P, Bendinelli C, et al. Minimally invasive video-assisted surgery of the thyroid gland: a preliminary report. *Langenbeck's Arch Sur* 2000; 385: 261-264.
19. Bellantone R, Lombardi P, Raffaelli M, et al. Central neck lymph node removal during minimally invasive video-assisted thyroidectomy for thyroid carcinoma: a feasible and safe procedure. *J Laparoendosc Adv Surg Tech* 2002; 12: 181-185.
20. Ikeda Y, Takami H, Niimi M, et al. Endoscopic thyroidectomy by the axillary approach. *Surg Endosc* 2001; 15: 1362-1364.
21. Kang SW, Jeong JJ, Yun JS, et al. Gasless endoscopic thyroidectomy using trans-axillary approach; surgical outcome of 581 patients. *Endocr J* 2009;56: 361-369.
22. Choe JH, Kim SW, Chung KW, et al. Endoscopic thyroidectomy using a new bilateral axillo-breast approach. *World J Surg* 2007; 31: 601-606.
23. Kang SW, Jeong JJ, Nam KH, et al. Robot-assisted endoscopic thyroidectomy for thyroid malignancies using a gasless transaxillary approach. *J Am Coll Surg* 2009; 209: e1-e7.
24. Lee J, Yun JH, Nam KH. Perioperative clinical outcomes after robotic thyroidectomy for thyroid carcinoma: a multicenter study. *Surg Endosc* 2011; 25: 906-912.
25. Lee KE, Rao J, Youn YK. Endoscopic thyroidectomy with da Vinci robot system using bilateral axillary breast approach (BABA) technique: our initial experience. *Surg Laparosc Endosc Percutan Tech* 2009; 19: e71-e75.
26. Lee KE, Koo DH, Im HJ, et al. Surgical completeness of bilateral axillo-breast approach robotic thyroidectomy: Comparison with conventional open thyroidectomy after propensity score matching. *Surgery* 2011; 150: 1266-1274.
27. Lin S, Chen ZH, Jiang HG, et al. Robotic thyroidectomy versus endoscopic thyroidectomy: a meta-analysis. *World J Surg Oncol* 2012; 9: 239.
28. Broome JT, Pomeroy S, Solorzano CC. Expense of Robotic Thyroidectomy. *Arch Surg* 2012; 147: 1102-1106.




## Radiology Quiz

### Radiology Quiz

Dr. KS TAI

Consultant Radiologist, Department of Radiology, Queen Mary Hospital, Hospital Authority



### Clinical History:

Eleven years old boy presented with headache for 1 month. Noted clumsiness in holding chopsticks and slurred speech. CT scan of the brain was performed. Please comment on the imaging findings, suggest further imaging evaluation if necessary and give your diagnosis/differential diagnosis. (Fig 1 & 2)

(See P.31 for answers)



Hong Kong Parkinson's Disease Foundation

香港柏金遜症基金

# 2013 Annual Scientific Meeting Update in Management of Parkinson's Disease

**Date : 7<sup>th</sup> Sep 2013 (Sat)**

**Time : 2:00pm - 5:00pm**

**Venue : Assembly Hall I & II, 4/F North Tower, YMCA of HK,  
41 Salisbury Road, Tsim Sha Tsui, Kowloon**

**Chairperson : Prof. Shu Leong Ho**

Opening Address

Update in Surgical Treatment of Parkinson's Disease

Dr. Benedict Taw

Update in Pharmacotherapy Management for Parkinson's Disease

Ms. Carol Fan

Tea Break

Development of Physiotherapy Service for Patients with Parkinson's Disease - Experience at QEH

Mr. Daniel Chau

Long term effects of pragmatic fall prevention programs in people with Parkinson's Disease

Ms. Irene Wong

Closing Remarks

**Registration Fee : Free Admission**

**For Enquiry :**

Only 150 seats are available on a first come first served basis. CME & CPD points will be accredited and certificate will be provided. Please register online [www.hkpdf.org.hk/activity\\_tc.php](http://www.hkpdf.org.hk/activity_tc.php).

: **2396 6468**

: [info@hkpdf.org.hk](mailto:info@hkpdf.org.hk)

Ms. Nathing Lai

Platinum Sponsors :

Gold Sponsor :

Bronze Sponsors :

Co-organizer :



Certificate Course on

# Primary Eye Care – From Infant to Elderly

Jointly organised by



The Federation of Medical Societies of Hong Kong



The Hong Kong Society of Professional Optometrists

Date	Topics	Speakers
2 Sep	Vision development and pediatric eye examination: a primary care approach	Ms. Yeung-chi HUANG <i>BSc (Hons) Optom, FAAO</i>
	Trend of common refractive errors and evidence-based interventions in retarding myopia progression in children	Dr. Wing-chun TANG <i>BSc (Hons) Optom, PhD</i>
9 Sep	Clinical diagnosis and management in common binocular disorders in children	Ms. Rufina Tin-yan CHAN <i>BOptom, MOptom, FAAO</i>
	Clinical assessment and management in learning-related visual perception problems	Ms. Mei-po LEUNG <i>BSc (Hons) Optom, FAAO</i>
16 Sep	Therapeutic use of contact lenses in pediatric patients	Mr. Wan-sang CHUI <i>BSc (Hons) Optom, MPhil, FAAO, FBCLA</i>
	Pediatric vision rehabilitation	Dr. Helen ENG <i>OD, FAAO</i>
23 Sep	Diagnosis and management of dry eyes	Mr. Wan-sang CHUI <i>BSc (Hons) Optom, MPhil, FAAO, FBCLA</i>
	Common contact lens complications and their clinical management in primary care practice	
30 Sep	Ocular complications in diabetic patients	Dr. Larry Hou-yan NG <i>OD, FAAO, FBCLA</i>
	Clinical applications of advanced retinal imaging technology	Dr. Sheung-shun NG <i>BSc (Hons) Optom, PhD, FAAO</i>
7 Oct	Common ocular signs and symptoms in elderly patients	Dr. Patrick Ho-wai CHU <i>BSc (Hons) Optom, PhD, FAAO</i>
	Vision and the prevention of fail in elderly patients	Dr. Allen Ming-yan CHEONG <i>BSc (Hons) Optom, PhD, FAAO</i>

**Enquiry :** The Secretariat of The Federation of Medical Societies of Hong Kong  
Tel.: 2527 8898 Fax: 2865 0345 Email: info@fmshk.org

Certificate Course on

# Renal Medicine 2013

Jointly organised by



The Federation of Medical Societies of Hong Kong



Hong Kong Society of Nephrology

Date	Topics	Speakers
6 Sep	Screening tests for renal disease including approach to proteinuria & haematuria	Dr. Bonnie Ching-ha KWAN Associate Professor, Department of Medicine & Therapeutics Prince of Wales Hospital, The Chinese University of Hong Kong
	How to interpret common investigation tests for renal disease	Dr. Chi-kwan WONG Associate Consultant, Department of Medicine Pamela Youde Nethersole Eastern Hospital
13 Sep	Update and management of hypertension	Dr. Hoi-wong CHAN Associate Consultant, Department of Medicine Queen Elizabeth Hospital
	Update on diabetic nephropathy	Dr. Kin-ye LO Associate Consultant, Department of Medicine and Geriatrics Kwong Wah Hospital
27 Sep	Drug prescribing in renal failure	Dr. Kai-ching HAU Associate Consultant, Department of Medicine and Geriatrics Tuen Mun Hospital
	Update and management of acute kidney injury	Dr. Terence Pok-siu YIP Associate Consultant, Department of Medicine Queen Mary Hospital & Tung Wah Hospital; Honorary Clinical Assistant Professor, The University of Hong Kong
4 Oct	Update and management of primary glomerulonephritis	Dr. Kai-ming CHOW Associate Consultant, Department of Medicine & Therapeutics Prince of Wales Hospital; Honorary Clinical Assistant Professor, The Chinese University of Hong Kong
	Renal protective strategy for chronic kidney disease	Dr. Tsz-Ling HO Associate Consultant, Department of Medicine Tseung Kwan O Hospital
11 Oct	ABC of peritoneal dialysis therapy	Dr. Man-fai LAM Associate Consultant, Honorary Assistant Professor, Department of Medicine Queen Mary Hospital
	ABC of hemodialysis therapy	Dr. Kwok-hong CHU Specialist in Nephrology St Teresa's Hospital
18 Oct	ABC of kidney donation	Dr. Sunny Sze-ho WONG Associate Consultant & Head of Division of Nephrology Department of Medicine and Geriatrics, United Christian Hospital
	ABC of renal transplantation	Dr. William LEE Associate Consultant, Department of Medicine and Geriatrics Princess Margaret Hospital

**Enquiry :** The Secretariat of The Federation of Medical Societies of Hong Kong  
Tel.: 2527 8898 Fax: 2865 0345 Email: info@fmshk.org



## 新聞稿

鑑於本港兒童的肥胖問題日益嚴重，本會早前委託香港中文大學香港亞太研究所進行一項有關學齡兒童肥胖的電話調查，訪問香港市民對肥胖成因及影響、兒童的運動及飲食習慣等的認知，藉此了解大眾對兒童肥胖的認識及提高社會各界對兒童肥胖問題的關注，讓兒童能更健康地成長。

是次調查以電話訪問 513 位 20-59 歲市民，其中 76.7% 受訪者有高中至大學學士或以上程度，70.1% 受訪者是已婚人士，35.8% 受訪者有就讀幼稚園及小學的子女。

### 1. 約三份一受訪市民認為香港兒童肥胖問題嚴重

衛生署學生健康服務的最新統計數字，二零一一至二零一二年的小學生過重及肥胖比例為 20.9%，比一九九七至一九九八學年的 16.4% 高出 4.5%，顯示此問題近年仍有惡化趨勢；是次問卷調查中，只有約三份一市民認為香港兒童肥胖問題嚴重，顯示社會各界對此問題要多加關注。

學齡兒童肥胖可引致糖尿病、高血壓、及較易被忽略的病症，如胃酸倒流、睡眠窒息綜合症及脂肪肝等疾病。根據中文大學調查顯示，約 77% 肥胖兒童曾患上脂肪肝，情況令人擔憂。另外，有研究數據顯示，自 1997 年至 2007 年間，本港肥胖兒童患上二型糖尿病的數字，增長幅度接近 10 倍。

### 2. 正確認識肥胖問題

根據是次調查結果顯示，本會表示雖有接近八成受訪者有高中至大學學士或以上學歷，但對肥胖的認知仍有待改善，包括：

- 1) 約四成人不知道睡眠不足可引致肥胖
- 2) 約五成人不知道餵哺母乳可減低兒童肥胖的機會
- 3) 約四成五人不知道兒童少年肥胖會增加成年時期肥胖的風險
- 4) 約有三成人不知道肥胖或可導致兒童患上情緒病

### 3. 健康體格由改變生活習慣開始

有見及此，本會提出以下八項建議，希望市民改變生活習慣，降低肥胖風險

- 1) 健康飲食習慣： 培養三低一高飲食習慣（低脂、低鹽、低糖及高纖）
- 2) 有足夠的運動： 每星期三次，每次半小時以上的帶氧運動
- 3) 恆常量度血壓： 兒童於不同年齡有不同的血壓標準，鼓勵家長定時為有肥胖問題的兒童安排量度血壓，並與醫生作相應
- 4) 有足夠的睡眠： 跟進建議學童一定要有足夠的睡眠，因缺乏睡眠可引致精神不足及肥胖
- 5) 鼓勵餵哺母乳： 母乳餵哺能減低兒童過胖的危機，避免餵養過量亦是預防兒童肥胖的重要一環
- 6) 定期身體檢查： 鼓勵家長為肥胖的兒童及青少年向醫生查詢相關健康狀況及作定期身體檢查，並積極控制體重，預防肥胖相關的併發症
- 7) 不吸煙或飲酒： 鼓勵家長以身作則，不要吸煙或飲酒
- 8) 推動各界合作： 本會促請飲食業界一同推動普及健康飲食文化，不單有更多食物供應商為學校提供營養餐單，更於食肆內提供更多健康食物



香港醫學組織聯合會於一九六五年成立，現有一百三十四個成員組織。創會成員為香港醫學會及英國醫學會香港分會。學會成員包括：醫生、牙醫、護士、藥劑師及各專職醫療團體。香港醫學組織聯合會致力為業界提供服務及聯系各屬會，積極向社會推廣健康教育資訊。

新聞稿由香港醫學組織聯合會發出：

1. 勞思傑醫生 香港醫學組織聯合會會長
2. 翟偉光醫生 香港醫學組織聯合會委員及週年學術會議主席  
兒科專科醫生
3. 余則文醫生 香港醫學組織聯合會基金董事
4. 周中武醫生 香港兒童腸胃肝臟及營養學會榮譽秘書
5. 黎大森醫生 精神科專科醫生
6. 張智良先生 香港營養學會會長
7. 黃潔怡女士 香港物理治療學會項目主任 及  
香港醫學組織聯合會董事會成員
8. 潘仕寶女士 香港執業營養師公會主席 及  
香港醫學組織聯合會董事會成員

聯絡代表：陳小姐 (Nancy)  
香港醫學組織聯合會秘書處行政經理  
電話：2821 3511

**FMSHK Press Conference on 23 Jun 2013**

In response to the increasing concern in child obesity, the FMSHK has commissioned Hong Kong Institute of Asia-Pacific Studies to conduct a telephone survey on child obesity in the territory in Jun, which covered the public perception and understanding of health issues related to obesity, exercise and dietary habit of local children. A press conference was held on 23 Jun 2013, presenting the survey result and recommendations on this issue. (The Press Release is on Page 23 )

With support of the media, the summary was reported in television news and 13 local newspapers. We hope to raise the awareness of child obesity amongst public, professionals and other industry partners, in order to encourage a healthy growth environment for our children.



**CERTIFICATE COURSE FOR NURSES AND ALLIED HEALTH PROFESSIONALS**

Certificate Course on

**Respiratory Medicine 2013**

CME/CNE Course

Course No. C220

Jointly organised by



Date	Topics	Speakers
18 Sep	Diagnostic investigations in the management of lung cancer	Dr. Johnny Wai-man CHAN <i>Consultant (Medicine)</i> Queen Elizabeth Hospital
25 Sep	Approach to the management of difficult pneumonias	Dr. Chung-ming CHU <i>Consultant (Medicine and Geriatrics)</i> United Christian Hospital
2 Oct	Extracorporeal Membrane Oxygenation (ECMO) in Management of Fulminant Pneumonia	Dr. Arthur Chun-wing LAU <i>Associate Consultant (Intensive Care Unit)</i> Pamela Youde Nettersole Eastern Hospital
9 Oct	Principles and Practice in Management of Respiratory Failure	Dr. Henry Kai-him KWOK <i>Associate Consultant (Occupational Medicine)</i> Queen Mary Hospital
16 Oct	Key Concepts and Updates in Pulmonary Rehabilitation	Dr. Raymond Wai-to LIU <i>Senior Medical Officer (Respiratory Medicine)</i> Ruttonjee and Tang Shiu Kin Hospitals
23 Oct	Lung Cancer Management: current state of knowledge	Dr. James Chung-man HO <i>Assistant Professor</i> Department of Medicine The University of Hong Kong

**Enquiry :** The Secretariat of The Federation of Medical Societies of Hong Kong  
Tel.: 2527 8898 Fax: 2865 0345 Email: info@fmshk.org



On 23 June 2013, the Federation successfully held our Annual Scientific Meeting 2013 in Sheraton Hotel and Towers, to achieve collaboration and information exchange among health care experts.

The theme this year was "Obesity-related disorders: an emerging epidemic", a very important health issue lately. A total of 17 talks delivered on a range of important aspects of obesity and complications from prevention to treatment, attracting a total attendance of 250 from medical, nursing, pharmaceutical and allied health professionals.

Officiating the opening ceremony, FMSHK was much privileged to have distinguished guests, comprising Dr. Ko Wing Man, BBS, JP, Secretary for Food and Health; Prof. Fok Tai Fai, Vice President of Hong Kong Academy of Medicine; Dr. Regina Ching, Consultant of Non Communicable Diseases of Department of Health; Dr. Kenneth Fu, President of Hong Kong Public Doctors' Association; Dr Sigmund Leung, JP, President of Hong Kong Dental Association; Ms. Ellen Ku, President of College of Nursing of Hong Kong; Mr. Gordon Cheung, President of Hong Kong Nutrition Association Ltd, and Dr. Raymond Lo, President of FMSHK. We designed a jigsaw puzzle with 8 important health messages to be brought home after the meeting by delegates and guests.

We would like to express our sincere gratitude to Dr. Raymond Lo, President of FMSHK and Dr. Mario Chak, Chairman of Organizing Committee, and to all our supporting sponsors. Last but not the least, heartfelt appreciation must be expressed to the following chairmen and speakers, and the FMSHK secretariat. We look forward to seeing you in the next Annual Scientific Meeting in 2014!

Prof. Alice KONG; Prof. Bernard CHEUNG; Prof. Brian TOMLINSON; Prof. Kwok-wai NG; Prof. YK WING; Dr. Regina CHING; Dr. Aaron YU; Dr. Annie KUNG; Dr. Ben FONG; Dr. Benjamin WONG; Dr. Chi-wai MAN; Dr. Chung-mo CHOW; Dr. Chun-on MOK; Dr. Jamie LAM; Dr. Jane CHAN; Dr. Mario CHAK; Dr. Maureen WONG; Dr. Peter PANG; Dr. Phyllis CHAN; Dr. Raymond LO; Dr. Sik-nin WONG; Dr. Vanessa NG; Dr. Yin-ko NG; Mr. Gordon CHEUNG; Ms Sally POON; Ms. Jenny NG







## The Hong Kong Society of Certified Prosthetist-Orthotists

In Hong Kong, Prosthetics and Orthotics (P&O) services have been provided to the community since the 60's. To better promote and enhance the quality of P&O services, the Hong Kong Society of Certified Prosthetist-Orthotists (HKSCPO) was established in 1995.

HKSCPO is an organization representing the prosthetics and orthotics professionals in Hong Kong. To become a full member of the Society, applicants have to complete a programme of Bachelor Degree in Prosthetics and/or Orthotics or equivalent, and with one year post-degree clinical experience under the supervision of a full member of HKSCPO. Full members are granted with the title - Certified Prosthetist-Orthotist, CPO(HK); Certified Prosthetist CP(HK) or Certified Orthotist CO(HK) subject to their area(s) of specialty. There are over 120 trained Prosthetist-Orthotists in Hong Kong practising in the private or public sector. Seventy-six of them are full members of HKSCPO and 5 are associated members.



Prosthetics and Orthotics are clinical applications of Biomedical Engineering, so the Society has also worked closely with the education institute and supports the broadening of P&O education to formulate a Bachelor of Science (Honours) Degree Programme in Biomedical Engineering, which has been duly recognised by the International Society for Prosthetics and Orthotics as an ISPO Category I Professional Training programme, and the Hong Kong Institution of Engineers as an accredited Engineering programme. We strongly believe that this evolution will bring the P&O development to its new dimensions.

For many years, our members collaborate with other local and mainland health care professionals to deliver voluntary services, such as the Western and Central District Health Festival (Hong Kong) and the Global Biomedical Service (Chinese Mainland). Moreover, the P&O professionals in Hong Kong also actively participate in various rehabilitation programmes in different areas of the Chinese Mainland. With the rapid development of P&O, HKSCPO will enhance its communication and collaboration with the other disciplines in Hong Kong and Chinese Mainland.

## The Hong Kong Paediatric Society

The Hong Kong Paediatric Society (HKPS) was firstly formed in 1962 by a group of devoted paediatricians with the Society emblem of a mother tending her child indicating our dedication to child health. HKPS became a member of the Federation of Medical Societies of Hong Kong in 1965.

Throughout the years, Paediatrics has been developed as one of the well-established specialties in Hong Kong with over 500 qualified fellows. The Hong Kong Journal of Paediatrics (HKJP) was firstly published by HKPS in 1984 as official journal and later on jointly organized by the Hong Kong College of Paediatricians (HKCP) and HKPS since 1996.

Year 2012 was the 50th Anniversary for both HKPS and development of Child Health in Hong Kong. HKPS has organized a series of professional and public activities as the half a century celebration for paediatrics in Hong Kong. Details of the 50th Anniversary programme can be found at the website: [http://www.medicine.org.hk/hkps/50anniversary/info\\_objectives.php](http://www.medicine.org.hk/hkps/50anniversary/info_objectives.php)

1. The Golden Jubilee Celebration with Oration on Child Health 2012 and Special Seminar on Centre of Excellence in Paediatrics in Hong Kong on 26th May 2012
2. Four Professional Fora from April to July 2012
3. Four Public Education sessions from May to Oct 2012
4. Multidisciplinary Conference on Child Health on 17th -19th Aug 2012, jointly organized with the American Academy of Pediatrics
5. Anniversary Banquet on 17th Aug 2012
6. 50th Anniversary Monograph
7. Time Capsule
8. Fun Fair for Public on 7th Oct 2012
9. MIMS Special Edition for 50th Anniversary of HKPS
10. Roadshow Education Video to Public
11. Two Health Surveys and Press Conferences
12. Child Health Policy (continue in 2013)



Formulating a Child Health Policy for Hong Kong is one of the major objectives of 50th Anniversary. A Steering Committee was set up to consolidate the ideas and four Drafting Groups have been formed to start the drafting procedure. A series of Professional Fora on child health are scheduled throughout this year to collect views from all stakeholders. In addition, HKPS has continued to organize two annual named lectures C. Elaine Field Memorial Lecture and J. Hutchison Memorial Lecture in March. The Annual Scientific meeting is scheduled in September this year. HKPS would continue our mission in promotion of child health and child advocacy.



Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
				<p><b>1</b></p> <p>★ HKMA Kowloon East Community Network- New Understanding in Treatment of Osteoporosis</p>	<p><b>2</b></p>	<p><b>3</b></p> <p>★ YCPG Youth Forum 2013</p>
<b>4</b>		<p>★ HKMA Council Meeting</p>	<p><b>7</b></p> <p>★ Hong Kong Neurosurgical Society Monthly Academic Meeting- Deep brain stimulation- more than Parkinson's disease</p> <p>★ HKMA Central, Western &amp; Southern Community Network- Modern Understanding in the Management of Acute Pain</p>	<p><b>8</b></p> <p>★ HKMA Hong Kong East Community Network- The Effectiveness of HIV Viral Load Monitoring Programs</p> <p>★ HKMA Kowloon East Community Network - Third Session of the "Certificate Course on Alzheimer's Disease"</p> <p>★ HKMA Structured CME Programme with Hong Kong Sanatorium &amp; Hospital Near 2013- Chemotherapy-induced Nausea and Vomiting</p> <p>★ FMSHK Executive Committee Meeting</p>	<p><b>9</b></p>	<p><b>10</b></p> <p>★ HKMA Kowloon East Community Network- Third Session of the CME Course for Health Personnel 2013: Management of Breast Cancer</p>
<b>11</b>		<p>★ HKMA Kowloon West Community Network - Medical and Surgical Treatment of Osteoarthritis of the Knee</p>	<p><b>14</b></p>	<p><b>15</b></p> <p>★ HKMA Kowloon East Community Network- Update On Management of Eczema</p> <p>★ HKFMS Foundation Committee Meeting</p>	<p><b>16</b></p>	<p><b>17</b></p>
<p>★ The 1st HKMA Dragon Boat Fun Day</p> <p><b>18</b></p>			<p><b>21</b></p> <p>★ HKMA Central, Western &amp; Southern Community Network- Andropause and its Management</p>	<p>★ HKMA Hong Kong East Community Network- Management of Insomnia and Mood Disorder</p> <p>★ HKMA Kowloon East Community Network- Final Session of the "Certificate Course on Alzheimer's Disease": Drug Therapy and Non-pharmacological Intervention for Dementia</p> <p>★ FMSHK Executive Committee &amp; Council Meeting</p> <p><b>22</b></p>	<p>★ HKMA Yau Tsim Mong Community Network- Management of Type 2 Diabetic Patients with Comorbidities</p> <p><b>23</b></p>	<p><b>24</b></p> <p>★ HKMA YTM Community Network- Certificate Course on Bringing Better Health to Our Community 2013 (Session 4)</p>
<p>★ HKMAPS 3rd Seasonal Competition</p> <p><b>25</b></p>		<p>★ HKMA Kowloon West Community Network- Latest Development in Modern Oral Contraceptives</p> <p><b>27</b></p>	<p><b>28</b></p>	<p>★ DH-HKMA CME on HIV &amp; Press Conference</p> <p><b>29</b></p>	<p><b>30</b></p>	<p><b>31</b></p>



Date / Time		Function	Enquiry / Remarks
<b>1 THU</b>	1:00 pm	<b>HKMA Kowloon East Community Network- New Understanding in Treatment of Osteoporosis</b> Organiser: HKMA Kowloon East Community Network, Speaker: Dr. IP Kai Yuen, Venue: Lei Garden Restaurant, Kwun Tong	Miss Hana YEUNG Tel: 2527 8285 1 CME point
<b>3 SAT</b>	9:00 am	<b>YCPG Youth Forum 2013</b> Organiser: The Hong Kong Calition of Professional Services, Venue: Run Run Shaw Hall, Hong Kong Academy of Medicine	Miss Phoebe WONG Tel: 2527 8285 0.5 CME point
<b>6 TUE</b>	8:00 pm	<b>HKMA Council Meeting</b> Organiser: The Hong Kong Medical Association, Chairman: Dr. TSE Hung Hing, Venue: HKMA Head Office (5/F., Duke of Windsor Social Service Building, 15 Hennessy Road, Hong Kong)	Ms. Christine WONG Tel: 2527 8285
<b>8 THU</b>	1:00 pm	<b>HKMA Hong Kong East Community Network- The Effectiveness of HPV Vaccine in National Immunization Programs</b> Organiser: HKMA Hong Kong East Community Network, Chairman: Dr. LI Keung, Speaker: Dr. SIU Shing Shun, Nelson, Venue: HKMA Head Office (5/F., Duke of Windsor Social Service Building, 15 Hennessy Road, Hong Kong)	Ms. Candice TONG Tel: 2527 8285 1 CME point
	1:00 pm	<b>HKMA Kowloon East Community Network – Third Session of the “Certificate Course on Alzheimer’s Disease”: Dementia Case Demonstration</b> Organiser: HKMA Kowloon East Community Network, Chairman: Dr. MA Ping Kwan, Danny, Speaker: Dr. CHAN Chun Chung, Ray, Venue: Lei Garden Restaurant, Kwun Tong	Miss Hana YEUNG Tel: 2527 8285 1 CME point
	2:00 pm	<b>HKMA Structured CME Programme with Hong Kong Sanatorium &amp; Hospital Year 2013– Chemotherapy-induced Nausea and Vomiting</b> Organiser: The Hong Kong Medical Association, Chairman: Dr. NG Fook Hong, Speaker: Dr. CHUA Tsin Tien, Daniel, Venue: HKMA Central Premises	CME Dept Tel: 2527 8452 1 CME point
	8:00 pm	<b>FMSHK Executive Committee Meeting</b> Organiser: The Federation of Medical Societies of Hong Kong, Venue: Council Chamber, 4/F, Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, Hong Kong	Ms. Nancy CHAN Tel: 2527 8898
<b>13 TUE</b>	1:00 pm	<b>HKMA Kowloon West Community Network - Medical and Surgical Treatment of Osteoarthritis of the Knee</b> Organiser: HKMA Kowloon West Community Network, Speaker: Dr. LEE On Bong, Venue: Panda Hotel, Tsuen Wan	Miss Hana YEUNG Tel: 2527 8285 1 CME point
<b>14 WED</b>	7:30 am	<b>Hong Kong Neurosurgical Society Monthly Academic Meeting– Deep brain stimulation- more than Parkinson’s disease</b> Organiser: Hong Kong Neurosurgical Society, Chairman: Dr. POON Tak Lap, Speaker: Dr. CHU Sai Lok, Caspar, Venue: Seminar Room, Ground Floor, Block A, Queen Elizabeth Hospital	Dr. Gilberto LEUNG Tel: 2255 3368 1.5 CME points
	1:00 pm	<b>HKMA Central, Western &amp; Southern Community Network- Modern Understanding in the Management of Acute Pain</b> Organiser: HKMA Central, Western & Southern Community Network, Speaker: Dr. WONG Kar Fai, Richard, Venue: HKMA Central Premises	Miss Hana YEUNG Tel: 2527 8285 1 CME point
<b>15 THU</b>	1:00 pm	<b>HKMA Kowloon East Community Network- Update On Management of Eczema</b> Organiser: HKMA Kowloon East Community Network, Speaker: Dr. CHAN Shu Yu, Venue: Crowne Plaza Hong Kong Kowloon East, Tseung Kwan O	Miss Hana YEUNG Tel: 2527 8285 1 CME point
	8:00 pm	<b>HKFMS Foundation Committee Meeting</b> Organiser: The Federation of Medical Societies of Hong Kong, Venue: Council Chamber, 4/F, Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, Hong Kong	Ms. Nancy CHAN Tel: 2527 8898
<b>17 SAT</b>	1:30 pm	<b>HKMA Kowloon East Community Network– Third Session of the CME Course for Health Personnel 2013: Management of Breast Cancer</b> Organiser: HKMA Kowloon East Community Network, Chairman: Dr. LEUNG Man Fuk, Speaker: Dr. CHAN Wing Wai, Sharon, Venue: United Christian Hospital	Ms. Cordy WONG Ms. Marina PUN Tel: 3513 3087 Tel: 3513 4888 1.5 CME points
<b>18 SUN</b>		<b>The 1st HKMA Dragon Boat Fun Day</b> Organiser: The Hong Kong Medical Association, Venue: Sai Kung	
<b>22 THU</b>	1:00 pm	<b>HKMA Hong Kong East Community Network- Management of Insomnia and Mood Disorder</b> Organiser: HKMA Hong Kong East Community Network, Chairman: Dr. YOUNG Ying Nam, Dominic, Speaker: Dr. CHANG Chi Lok, Venue: HKMA Head Office (5/F., Duke of Windsor Social Service Building, 15 Hennessy Road, Hong Kong)	Ms. Candice TONG Tel: 2527 8285 1 CME point
	1:00 pm	<b>HKMA Kowloon East Community Network- Final Session of the “Certificate Course on Alzheimer’s Disease”: Drug Therapy and Non-pharmacological Intervention for Dementia</b> Organiser: HKMA Kowloon East Community Network, Chairman: Dr. AU Ka Kui, Gary, Speaker: Dr. TAM Kui Fu, Stanley, Venue: Lei Garden Restaurant, Kwun Tong	Miss Hana YEUNG Tel: 2527 8285 1 CME point
	7:00 pm	<b>FMSHK Executive Committee &amp; Council Meeting</b> Organiser: The Federation of Medical Societies of Hong Kong, Venue: Council Chamber, 4/F, Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, Hong Kong	Ms. Nancy CHAN Tel: 2527 8898
<b>23 FRI</b>	1:00 pm	<b>HKMA Yau Tsim Mong Community Network- Management of Type 2 Diabetic Patients with Comorbidities</b> Organiser: HKMA Yau Tsim Mong Community Network, Chairman: Dr. LAM Tzit Yuen, David, Speaker: Dr. CHAN Wing Bun, Venue: Jade Ballroom, Level 2, Eaton Smart, Hong Kong, 380 Nathan Road, Kowloon	Ms. Candice TONG Tel: 2527 8285 1 CME point
<b>25 SUN</b>	2:00 pm	<b>HKMAPS 3rd Seasonal Competition</b> Organiser: The Hong Kong Medical Association Photographic Society, Chairman: Dr. PANG Lai Man, Amy, Venue: HKMA Head Office (5/F., Duke of Windsor Social Service Building, 15 Hennessy Road, Hong Kong)	Miss Nadio HO Tel: 2527 8285
<b>27 TUE</b>	1:00 pm	<b>HKMA Kowloon West Community Network- Latest Development in Modern Oral Contraceptives</b> Organiser: HKMA Kowloon West Community Network, Chairman: Dr. WONG Wai Hong, Speaker: Dr. KUN Ka Yan, Venue: Crystal Room I-III, 30/F, Panda Hotel, 3 Tsuen Wah Street, Tsuen Wan, N.T	Miss Hana YEUNG Tel: 2527 8285
<b>28 WED</b>	1:00 pm	<b>HKMA Central, Western &amp; Southern Community Network- Andropause and its Management</b> Organiser: HKMA Central, Western & Southern Community Network, Speaker: Dr. YIP Wai Chun, Andrew, Venue: HKMA Central Premises	Miss Hana YEUNG Tel: 2527 8285 1 CME point
<b>29 THU</b>	1:00 pm	<b>DH-HKMA CME on HIV &amp; Press Conference</b> Organiser: The Hong Kong Medical Association, Venue: HKMA Central Premises	Ms SHU Bo Yee Tel: 3143 7200 1.5 CME points
<b>31 SAT</b>	1:00 pm	<b>HKMA YTM Community Network- Certificate Course on Bringing Better Health to Our Community 2013 (Session 4)</b> Organiser: HKMA Yau Tsim Mong Community Network and Department of Family Medicine & General Outpatient Clinic and Department of Medicine, Kowloon Central Cluster, Speaker: Dr. LAM Chun; Dr. John CHAN, Venue: Block M, Lecture Theatre, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong	Ms. Candice TONG Tel: 2527 8285




## Answers to Radiology Quiz

### Diagnosis: Meningioma

#### CT findings:

1. Large predominantly isodense right posterior fossa mass abutting the tentorium with mass effect on the adjacent cerebellum and brainstem.
2. Compression of the 4th ventricle with mildly dilated 3rd and lateral ventricles.
3. No intralésional calcification or haemorrhage.
4. No skull vault hyperostosis.

#### MRI findings: (Fig 3&4)



1. Large T1W hypointense and T2W heterogeneous hyperintense right CP angle mass abutting the tentorium.
2. Moderate largely homogeneous contrast enhancement without dural tail.
3. Mass effect with compression of the 4th ventricle, brainstem and cerebellum.
4. Mild hydrocephalus with T2W hyperintense transependymal oedema.
5. Slight extension to normal size right IAM.

#### Operative findings:

Surgical excision of the right CP angle mass was performed and pathology revealed WHO Grade I meningioma.

#### Discussion:

Meningiomas are uncommon childhood tumours. In general, paediatric meningiomas are commonly quoted as constituting 1.5 - 1.8% of all meningiomas and 0.4 - 4.1% of all childhood brain tumours. In contrast to adult meningiomas, there is no female preponderance among paediatric meningiomas, and in certain series male subjects appear to outnumber their female counterparts.

Childhood meningiomas are characteristically known to have non-specific symptoms and diagnosis is often difficult. The elasticity of the skull and non-cooperation among children compounds the problem. Quite often a local swelling of the cranial vault may be the first sign. Common clinical manifestations of paediatric meningiomas include signs of increased intracranial tension, focal neurological deficits, seizures and other signs based on lesion location.

The incidence of calcification and hyperostosis in CT scan is high especially in those paediatric meningiomas associated with neurofibromatosis (NF). On CT scanning, hyperostosis of the overlying bone is seen in 50% of tumours and 50% have intra-tumoural calcification. Magnetic resonance (MR) characteristics of paediatric meningiomas are similar to adult meningiomas. On MR imaging, the tumours are usually isointense to hypointense on T1, iso- to hypointense on T2 and exhibit good contrast enhancement. T2 hyperintensities, if seen, denote microcystic changes, dilated blood vessels, and high cellularity and usually suggest a syncytial or angiomatous variant. Tumour ADC values do not help to predict tumour grade or clinical type. Presence of a dural tail sign on MR imaging is not obvious in the majority of paediatric meningiomas. Convexity and parasagittal meningiomas are the most frequent sites (>50%) for meningiomas in both adults as well as in several series of paediatric meningiomas. However, paediatric meningiomas are known to favour uncommon sites like the skull base and posterior fossa locations. A second feature that seems to be typical of the paediatric age is the higher incidence of meningiomas located within the ventricular system or lacking any apparent dural attachment like deep in the Sylvian fissure. Other unique aspects reported for paediatric meningiomas are large tumour size, cyst formation and tendency to recur. Childhood meningiomas are known to have a high incidence of atypical histopathology especially the clear cell variant and the papillary variant. The association between NF-2 and meningioma is well known, and they may share common mechanisms of pathogenesis. The possibility of NF2 should be considered in any child with a meningioma and approximately 25 - 40% of children with meningiomas have NF2.

The causal relationship between radiation and paediatric meningioma is well established. Current findings suggest a nearly ten-fold relative risk for children with radiation exposure over those without such exposure. Radiation induced meningiomas typically present at an earlier age, arise within the prior irradiation field by definition, are more likely to be multifocal and exhibit higher degrees of atypia and mitosis. There is also some suggestion of a dose effect, with higher levels of radiation exposure being associated with shorter latency periods for development of meningiomas.

The goal of treatment in meningiomas is total resection with wide dural clearance. Adjuvant radiotherapy appears to be beneficial after incomplete excision of meningiomas in adults, but it is rather risky to use radiotherapy for benign and partially excised cerebral lesions during childhood. Reoperation is thought to be better than adjuvant therapy. The clinical evolution of meningiomas in children is not reliably predictable and remains a problem. Consequently, childhood meningiomas are considered to carry a worse prognosis (35% 10 year survival rate) than meningiomas in the adult population. Favourable prognostic factors include younger age (< 10 years), superficial location, total excision and absence of neurofibromatosis. The location and extent of excision appear to be more important than the histopathology in predicting outcome.

#### References:

1. Menon G, Nair S, Sudhir J, Rao BRM, Mathew A, Bahuleyan B. Childhood and adolescent meningiomas: a report of 38 cases and review of literature. *Acta Neurochir* 2009; 151:239-44.
2. Pinto PS, Huisman TA, Ahn E, Jordan LC, Burger P, Cohen KJ, Patay Z, Tekes A. Magnetic resonance imaging features of meningiomas in children and young adults: a retrospective study. *J Neuroradiol* 2012; 39:218-26

Dr. KS TAI

Consultant Radiologist, Department of Radiology, Queen Mary Hospital, Hospital Authority

**Certificate Course for helping professionals including medical staff, social workers, teachers**

**Certificate Course on**

# Crisis Management and Counselling Skills

| CME/CNE Course | Course No. C225

**Jointly organised by**

The Federation of Medical Societies of Hong Kong

Hong Kong Society for Nursing Education

**Objectives:**

Crisis Intervention is a common knowledge to management in modern society. Besides natural and accidental disasters, technological and human crimes bring crisis to victims and their families. Crisis intervention in forms of critical incident debriefing, crisis interventions and acute stress reduction aim to assisting victims to cope with the impact of sudden crisis and to prevent the development of post-traumatic stress disorder and other forms of mental health problems. The participants will learn basic assessment and intervention in managing pre and post crisis situations.

Date	Topics	Speaker
21 Aug	1. Crisis scope and definition 2. Assessment 3. The qualities of a crisis worker	Dr. Albert Chan Founder and Director, Institute for Family and Psychology & Clinical and Counseling Psychologist
28 Aug	Critical incident debriefing and crisis intervention	
11 Sep	Basic Counselling skill and CBT	

**Date :** 21, 28 August 2013 and 11 September 2013 (Every Wednesday)  
**Time :** 7:00 p.m. – 10:00 p.m.  
**Venue :** Lecture Hall, 4/F., Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, Hong Kong  
**Language Media :** Cantonese (Supplemented with English)  
**Course Fee :** HK\$750 (3 sessions)  
**Certificate :** Awarded to participants with a minimum attendance of 70%  
**Enquiry :** The Secretariat of The Federation of Medical Societies of Hong Kong  
 Tel.: 2527 8898 Fax: 2865 0345 Email: info@fmshk.org

**CME / CPD Accreditation in application**

A total of 9 CNE points for the whole course and the points will be awarded according to the number of hours attended.  
 Application form can be downloaded from website: <http://www.fmshk.org>

**The Federation of Medical Societies of Hong Kong**  
 4/F Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, HK  
 Tel: 2527 8898 Fax: 2865 0345

**President**  
 Dr. LO See-kit, Raymond 勞思傑醫生

**1st Vice-President**  
 Prof. CHAN Chi-fung, Godfrey 陳志峰教授

**2nd Vice-President**  
 Dr. CHAN Sai-kwing 陳世燭醫生

**Hon. Treasurer**  
 Mr. LEE Cheung-mei, Benjamin 李祥美先生

**Hon. Secretary**  
 Dr. NG Yin-kwok 吳賢國醫生

**Immediate Past President**  
 Dr. FONG To-sang, Dawson 方道生醫生

**Executive Committee Members**

Dr. CHAK Wai-kwong, Mario	翟偉光醫生
Dr. CHAN Chun-kwong, Jane	陳真光醫生
Dr. CHAN Hau-ngai, Kingsley	陳厚毅醫生
Prof. CHIM Chor-sang, James	詹楚生教授
Dr. FONG Yuk-fai, Ben	方玉輝醫生
Dr. HUNG Che-wai, Terry	洪致偉醫生
Ms. KU Wai-yin, Ellen	顧慧賢女士
Dr. LO Sze-ching, Susanna	盧時楨醫生
Dr. MAN Chi-wai	文志衛醫生
Dr. MOK Chun-on	莫鎮安醫生
Dr. WONG Mo-lin, Maureen	黃慕蓮醫生
Ms. YAP Woan-tyng, Tina	葉婉婷女士
Dr. YU Chau-leung, Edwin	余秋良醫生
Dr. YUNG Shu-hang, Patrick	容樹恆醫生

**Founder Members**

**British Medical Association (Hong Kong Branch)**  
 英國醫學會 (香港分會)

**President**  
 Dr. LO See-kit, Raymond 勞思傑醫生

**Vice-President**  
 Dr. WU, Adrian 鄺揚源醫生

**Hon. Secretary**  
 Dr. HUNG Che-wai, Terry 洪致偉醫生

**Hon. Treasurer**  
 Dr. Jason BROCKWELL

**Council Representatives**

Dr. LO See-kit, Raymond	勞思傑醫生
Dr. CHEUNG Tse-ming	張子明醫生

**The Hong Kong Medical Association**  
 香港醫學會

**President**  
 Dr. TSE Hung-hing 謝鴻興醫生

**Vice-Presidents**

Dr. CHAN Yee-shing, Alvin	陳以誠醫生
Dr. CHOW Pak-chin	周伯展醫生

**Hon. Secretary**  
 Dr. LAM Tzit-yuen 林哲玄醫生

**Hon. Treasurer**  
 Dr. LEUNG Chi-chiu 梁子超醫生

**Council Representatives**

Dr. CHAN Yee-shing	陳以誠醫生
Dr. CHOW Pak-chin	周伯展醫生

**Chief Executive**  
 Mrs. LEUNG, Yvonne 梁周月美女士  
 Tel: 2527 8285 (General Office)  
 2527 8324 / 2536 9388 (Club House in Wanchai / Central)  
 Fax: 2865 0943 (Wanchai), 2536 9398 (Central)  
 Email: hkma@hkma.org Website: <http://www.hkma.org>

**The HKFMS Foundation Limited** 香港醫學組織聯合會基金

**Board of Directors**

**President**  
 Dr. LO See-kit, Raymond 勞思傑醫生

**1st Vice-President**  
 Prof. CHAN Chi-fung, Godfrey 陳志峰教授

**2nd Vice-President**  
 Dr. CHAN Sai-kwing 陳世燭醫生

**Hon. Treasurer**  
 Mr. LEE Cheung-mei, Benjamin 李祥美先生

**Hon. Secretary**  
 Dr. NG Yin-kwok 吳賢國醫生

**Directors**

Mr. CHAN Yan-chi, Samuel	陳恩賜先生
Prof. CHIM Chor-sang, James	詹楚生教授
Ms. KU Wai-yin, Ellen	顧慧賢女士
Dr. WONG Mo-lin, Maureen	黃慕蓮醫生
Dr. YU Chak-man, Aaron	余則文醫生

HONG KONG SANATORIUM & HOSPITAL  
 LI SHU PUI SYMPOSIUM 2013  
**RECENT ADVANCES  
 IN MEDICAL PRACTICE**



**Date : 15 September 2013 (Sunday)**  
**Venue : Ballroom, JW Marriott Hotel Hong Kong**

08:50 – 09:00	Welcome		Dr. Walton LI
09:00 – 09:30	<b>Keynote Lecture 1: The Right Doctor for the Right Procedure</b>		Dr. Joseph CHAN
	<b>Symposium 1 Precise and Less Invasive Procedures</b>	Chairperson	Dr. William WEI   Dr. Vincent KWOK
09:30 – 09:45	Cardiac Intervention		Dr. Duncan HO
09:45 – 10:00	Application of Robot in General Surgery		Dr. Michael LI
10:00 – 10:15	Makoplasty – Optimal Option of Joint Replacement		Dr. Stephen WU
10:15 – 10:30	Endoscopic Surgery for the Oesophagus		Prof. Simon LAW (HKU)
10:30 – 10:40	Q & A		
10:40 – 11:00	Coffee Break		
	<b>Symposium 2 Diagnostics</b>	Chairperson	Dr. LAI Kar Neng   Dr. WONG Wai Sang
11:00 – 11:15	Ultrasound in Head & Neck Medical Practice-Is There a Limit?		Prof. Anil T. AHUJA (CUHK)
11:15 – 11:30	Bronchoscopy and Beyond		Dr. LAM Bing
11:30 – 11:45	How Would Prenatal Diagnosis Make a Difference in Modern Obstetrics?		Dr. Danny LEUNG
11:45 – 12:00	Updates on Digestive Endoscopy – Diagnosis and Treatment		Dr. Angus CHAN
12:00 – 12:10	Q & A		
12:10 – 13:00	<b>Li Shu Pui Lecture How MR is Changing Medical Decisions</b>	Chairperson	Dr. Gladys LO <b>Prof. Dieter ENZMANN (UCLA)</b>
13:00 – 14:00	Lunch		
	<b>Symposium 3 Genetics</b>	Chairperson	Dr. Edmond MA   Dr. Raymond LIANG
14:00 – 14:15	Gems and Caveats of Next Generation Sequencing in Molecular Diagnosis		Dr. Chris CHAN
14:15 – 14:30	Paediatric Genetics – All About the “Next Generation”		Dr. Brian CHUNG (HKU)
14:30 – 14:45	An Update on Hereditary Breast Cancer		Dr. Ava KWONG (HKU)
14:45 – 14:55	Q & A		
14:55 – 15:25	<b>Keynote Lecture 2 : Liver Surgery in Private Hospital</b>		Dr. FAN Sheung Tat
15:25 – 15:45	Coffee Break		
	<b>Symposium 4 GP Forum</b>	Chairperson	Dr. Billy CHIU   Dr. CHAN On On
15:45 – 16:00	Corneal Transplant – Indications & Results		Dr. Arthur CHENG
16:00 – 16:15	Modern Oncology Treatments		Dr. KWAN Wing Hong
16:15 – 16:30	Contemporary Dental Implant Therapy – An Immediate Solution		Dr. Alfred LAU
16:30 – 16:45	Allergen Desensitization		Dr. LEE Tak Hong
16:45 – 17:00	PET for Non Malignant Diseases		Dr. Garrett HO

*\*Content is subject to change without prior notice*

RESERVE YOUR PLACE NOW

Registration: 2835 8800

CME Accreditation Pending | CPD (6 points) | CNE (5.5 points)



Relieve GERD  
& leave them  
to dream



NEW



**DEXILANT**  
dexlansoprazole

30 MG | 60 MG DELAYED RELEASE CAPSULES

### A PPI with Dual Delayed Release Technology for the management of GERD

- › With innovative dual releases of active drug to provide significantly extended heartburn control<sup>1,2</sup>
- › Effective across the spectrum of GERD<sup>3,4,6</sup>
- › Superior efficacy in the management of NERD<sup>5</sup>
- › Effectively maintaining healed erosive esophagitis and improving quality of life<sup>6,7</sup>
- › Lifestyle-friendly PPI: once daily, taken with or without food<sup>1,8,9</sup>
- › Acceptable safety and tolerability profiles with less clopidogrel interaction<sup>1,10</sup>

For further information, consult full prescribing information.

Reference: 1. Dexilant prescribing information (DEX0912 PIHK). 2. Wittbrodt ET et al., Clin Exp Gastroenterol 2009;2:117-28. 3. Fass R et al., Aliment Pharmacol Ther 2009;29:1261-72. 4. Sharma P et al., Aliment Pharmacol Ther 2009;29:731-41. 5. Wu MS et al., Aliment Pharmacol Ther 2013;38:190-201. 6. Metz DC et al., Aliment Pharmacol Ther 2009;29:742-54. 7. Howden CW et al., Aliment Pharmacol Ther 2009;30:895-907. 8. Lee RD et al., Aliment Pharmacol Ther 2009;29:824-33. 9. Lee RD et al., Aliment Pharmacol Ther 2010;31:1001-11. 10. Frelinger AL et al., J Am coll Cardiol 2012;59:1304-11.

\*96% of patient on Dexlansoprazole 60mg achieved 24-h heartburn-free days<sup>5</sup>



**Takeda Pharmaceuticals (Hong Kong) Limited**  
23th & 24th Floor, East Exchange Tower,  
38 Leighton Road, Causeway Bay, Hong Kong  
Tel : (852) 2133 9800 Fax : (852) 2856 2728  
www.takeda.com